WO2003074050A1 - Thiazole and oxazole derivatives which modulate ppar activity - Google Patents

Thiazole and oxazole derivatives which modulate ppar activity Download PDF

Info

Publication number
WO2003074050A1
WO2003074050A1 PCT/IB2003/000708 IB0300708W WO03074050A1 WO 2003074050 A1 WO2003074050 A1 WO 2003074050A1 IB 0300708 W IB0300708 W IB 0300708W WO 03074050 A1 WO03074050 A1 WO 03074050A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
phenyl
compound
trifluoromethyl
thiazol
Prior art date
Application number
PCT/IB2003/000708
Other languages
French (fr)
Inventor
Xue-Min Cheng
Noe Ouano Erasga
Gary Frederick Filzen
Andrew George Geyer
Chitase Lee
Bharat Kalidas Trivedi
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2003572567A priority Critical patent/JP2005528348A/en
Priority to EP03702943A priority patent/EP1482935B1/en
Priority to AU2003206059A priority patent/AU2003206059A1/en
Priority to CN03805413.2A priority patent/CN1750820A/en
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Priority to APAP/P/2004/003124A priority patent/AP2004003124A0/en
Priority to MXPA04007564A priority patent/MXPA04007564A/en
Priority to BR0308277-6A priority patent/BR0308277A/en
Priority to KR10-2004-7013951A priority patent/KR20040091693A/en
Priority to DE60323060T priority patent/DE60323060D1/en
Priority to EA200400943A priority patent/EA200400943A1/en
Priority to CA002478520A priority patent/CA2478520A1/en
Publication of WO2003074050A1 publication Critical patent/WO2003074050A1/en
Priority to IS7377A priority patent/IS7377A/en
Priority to TNP2004000168A priority patent/TNSN04168A1/en
Priority to NO20044242A priority patent/NO20044242L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26Radicals substituted by sulfur atoms

Definitions

  • the present invention relates to compounds and pharmaceutical formulations that can be used to treat conditions mediated by nuclear hormone receptors, more specifically, to compounds and pharmaceutical formulations that modulate PPAR activity.
  • Hypercholesterolemia, hyperlipidemia, and diabetes are well recognized risk factors in the onset of atherosclerosis and coronary heart disease.
  • Hypercholesterolemia and hyperlipidemia are characterized by excessively high levels of blood cholesterol and lipids.
  • the blood cholesterol pool is generally dependent on dietary uptake of cholesterol from the intestine and biosynthesis of cholesterol throughout the body, especially the liver.
  • the majority of cholesterol in plasma is carried on apolipoprotein B-containing lipoproteins, such as low-density lipoproteins (LDL) and very-low-density lipoproteins (NLDL).
  • LDL low-density lipoproteins
  • NLDL very-low-density lipoproteins
  • the risk of coronary artery disease in man increases when LDL and VLDL levels increase.
  • high levels of cholesterol carried in high-density lipoproteins (HDL) is protective against coronary artery disease (Am. J. Med., 1977;62:707-714).
  • statins represent perhaps the most important class of lipid-lowering drugs.
  • statins include atorvastatin, lovastatin, pravastatin, and simvastatin. The effectiveness of these compounds depends on LDL receptor regulation.
  • Other important antilipidemia drugs include fibrates such as gemfibril and clofibrate, bile acid sequestrants such as cholestyramine and colestipol, probucol, and nicotinic acid analogs.
  • sulfonylureas are generally used to stimulate insulin.
  • the biguanide metformin is generally used to improve insulin sensitivity and to decrease hepatic glucose output.
  • Acarbose is used to limit postprandial hyperglycemia.
  • Thiazolidine 2,4 diones are used to enhance insulin action without increasing insulin secretion.
  • PPAR Peroxisome Proliferator Activation Receptors
  • PPARs are implicated in a number of biological processes and disease states including hypercholesterolemia, hyperlipidemia, and diabetes.
  • PPARs are members of the nuclear receptor superfamily of transcription factors that includes steroid, thyroid, and vitamin D receptors. They play a role in controlling expression of proteins that regulate lipid metabolism.
  • the PPARs are activated by fatty acids and fatty acid metabolites.
  • PPAR ⁇ for instance, is expressed most abundantly in adipose tissue and at lower levels in skeletal muscle, heart, liver, intestine, kidney, vascular endothelial and smooth muscle cells as well as macrophages.
  • PPAR receptors are associated with regulation of insulin sensitivity and blood glucose levels, macrophage differentiation, inflammatory response, and cell differentiation. Accordingly, PPARs have been associated with obesity, diabetes, carcinogenesis, hyperplasia, atherosclerosis, hyperlipidemia, and hypercholesterolemia.
  • PPAR ⁇ agonists lower plasma triglycerides and LDL cholesterol and are therefore useful in treating hypertriglyceridemia, hyperlipidemia and obesity.
  • PPAR ⁇ is associated with the development of non-insulin-dependent diabetes mellitus (NIDDM), hypertension, coronary artery disease, hyperlipidemia and certain malignancies.
  • NIDDM non-insulin-dependent diabetes mellitus
  • activation of PPAR ⁇ has been demonstrated to increase HDL levels.
  • a PPAR ⁇ selective agonist was reported to have shown a dose-related increase in serum HDL-C and decrease in LDL-C and VLDL-TG in insulin-resistant middle aged rhesus monkeys. (W. R. Oliver et al., PNAS, v. 98, pp. 5306-531 1 , 2001)
  • Antilipidemic and antidiabetic agents are still considered to have non-uniform effectiveness.
  • the effectivieness of antidiabetic and antilipidemic therapies is limited, in part because of poor patient compliance due to unacceptable side effects. These side effects include diarrhea and gastrointestinal discomfort, and in the case of anti diabetics, edema, hypoglycemia and hepatoxicity. Furthermore, each type of drug does not work equally well in all patients.
  • the present invention provides compounds capable of modulating PPAR activity.
  • Compounds of the present invention are described by Formula I:
  • W is O, S, CR ..V R.6°, -(CH 2 ) p -cycloalkylene, or -(CH 2 ) p -heterocycloalkylene;
  • X° and X 1 are independently O or S;
  • Ar 1 is a unsubstituted or substituted aryl or heteroaryl
  • R 1 , R 2 , R 3 , and R 4 are hydrogen, lower alkyl, lower alkoxy, haloalkyl,-O- (CH 2 ) P CF 3 , halogen, nitro, cyano, -OH, -SH, -CF 3 , -S(O) p alkyl, S(O) p aryl, - (CH 2 ) m OR 7 , -(CH 2 ) m NR 8 R 9 , -COR 7 , -CO 2 H, -CO 2 R 7 , or -NR 8 R 9 ;
  • R 5 and R 6 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl, or joined together to form a 3 to 7 member cycloalkyl or cycloalkenyl;
  • R 7 is independently hydrogen, alkyl, alkenyl, alkynyl, or aryl
  • R 8 and R 9 are each independently hydrogen, alkyl, alkenyl, alkynyl, -COalkyl, -COaryl, cycloalkyl, -CO 2 alkyl, -CO 2 aryl, -SO alkyl, -SO 2 aryl, or joined together to form a 4 to 7 member ring having 1 to 3 heteroatoms;
  • R 2 and R 3 are not hydrogen.
  • a pharmaceutical composition comprising a compound of Formula I and one or more pharmaceutically acceptable carriers, diluents, or excipients is provided.
  • a method of treating, preventing or controlling hypercholesteremia and hyperlipidemia in a mammal comprises administering to the mammal in need thereof a therapeutically effective amount of the compounds of the present invention.
  • a method for treating, preventing, or controlling obesity is provided.
  • a method for treating, preventing, or controlling hyperglycemia is provided.
  • a method for treating, preventing, or controlling atherosclerosis is provided.
  • a method for treating, preventing, or controlling hypertriglyceridemia is provided.
  • a method for treating, preventing, or controlling hyperinsulinemia is provided.
  • a method for treating, preventing, or controlling diabetes is provided.
  • a therapeutically effective amount of the compounds of the present invention are administered to the mammal in need thereof.
  • alkyl, alkoxy, alkenyl, alkynyl, etc. denote both straight and branched groups; but reference to an individual radical such as “propyl” embraces only the straight chain radical, a branched chain isomer such as “isopropyl” being specifically referred to.
  • alkyl refers to a straight or branched hydrocarbon of from 1 to 1 1 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, and the like.
  • Useful alkyl groups have from 1 to 6 carbon atoms (C ⁇ -C 6 alkyl).
  • lower alkyl refers to a subset of alkyl which means a straight or branched hydrocarbon radical having from 1 to 6 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, and the like.
  • lower alkyl is referred to as "Ci-C ⁇ alkyl.”
  • haloalkyi refers to a lower alkyl radical, as defined above, bearing at least one halogen substituent, for example, chloromethyl, fluoroethyl, trifluoromethyl, or 1 ,1 ,1-trifluoroethyl and the like.
  • Haloalkyi can also include perfluoroalkyl wherein all hydrogens of a loweralkyl group are replaced with fluorine atoms.
  • alkenyl means a straight or branched unsaturated hydrocarbon radical having from 2 to 12 carbon atoms and includes, for example, ethenyl, 1- propenyl, 2-propenyl, 1 -butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 3-methyl-3- butenyl, ] -hexenyl, 2-hexenyl, 3-hexenyl, 3-heptenyl, 1-octenyl, 1 -nonenyl, 1- decenyl, 1 -undecenyl, 1-dodecenyl, and the like.
  • alkynyl means a straight or branched hydrocarbon radical having from 2 to 12 carbon atoms having at least one triple bond and includes, for example, 1-propynyl, 1 -butynyl, 3-butynyl, 1 -pentynyl, 3-pentynyl, 3-methyl-3-butynyl, 1- hexynyl, 3-hexynyl, 3-heptynyl, 1-octynyl, 1-nonynyl, 1-decynyl, 1 -undecynyl, 1- dodecynyl, and the like.
  • alkylene refers to a divalent group derived from a straight or branched chain saturated hydrocarbon having from 1 to 10 carbon atoms by the removal of two hydrogen atoms, for example methylene, 1 ,2-ethylene, 1,1- ethylene, 1 ,3-propylene, 2,2- dimethylpropylene, and the like.
  • the alkylene groups of this invention can be optionally substituted.
  • Useful alkylene groups have from 1 to 6 carbon atoms (C ⁇ -C 6 alkylene).
  • cycloalkylene refers to a divalent group derived from a cyclic saturated hydrocarbon having from 3 to 8 carbon atoms by the removal of two hydrogen atoms.
  • the cycloalkylene groups of this invention can be optionally substituted.
  • the cycloalkylene group can also be substituted with one or more of the substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, -O(CH 2 ) 0 .
  • cycloalkylene groups have from 3 to 6 carbon atoms (C 3 -C 6 alkyl).
  • halogen includes chlorine, fluorine, bromine, and iodine.
  • heteroatom as used herein represents oxygen, nitrogen, or sulfur (O, N, or S) as well as sulfoxyl or sulfonyl (SO or SO 2 ) unless otherwise indicated.
  • heterocycloalkylene refers to a cycloalkylene group that includes one or more heteroatoms such as oxygen, sulfur, or nitrogen.
  • hydrocarbon chain refers to a straight hydrocarbon of from 2 to 6 carbon atoms.
  • the hydrocarbon chain is optionally substituted with one or more substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, - O(CH 2 ) 0 .
  • heterocycle means a saturated or unsaturated mono- or polycyclic (i.e. bicyclic) ring inco ⁇ orating one or more (i.e.
  • heterocycle is optionally substituted with -OH, - O(alkyl), SH, S(alkyl), amine, halogen, acid, ester, amide, amidine, alkyl ketone, aldehyde, nitrile, fluoroalkyl, nitro, sulphone, sulfoxide or C
  • Suitable monocyclic heterocycles include, but are not limited to substituted or unsubstituted thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazoiyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, piperidinyl, pyrrolidinyl, piperazinyl, azetidinyl, aziridinyl, mo ⁇ holinyl, thietanyl, oxetaryl.
  • Examples of monocyclic diheterocycles include, but are not limited to, 1-, 2- , 4-, or 5-imidazolyl, 1-, 3-, 4-, or 5-pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5- isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5-isoxazolyl, 1, 3-, or 5-triazolyl, 1-, 2-, or 3-tetrazolyl, 2-pyrazinyl, 2-, 4-, or 5-pyrimidinyl, 1- or 2-piperazinyl, 2-, 3-, or 4- mo ⁇ holinyl.
  • bicyclic heterocycles include, but are not limited to indolizinyl, isoindolyl, benzofuranyl, benzothienyl, benzoxazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, quinazolinyl, 1-, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 1-, 2-, 3-, 5-, 6-, 7-, or 8-indolizinyl, 1-, 2-, 3-, 4-, 5-, 6-, or 7-isoindolyl, 2-, 3-, 4-, 5-, 6-, or 7- benzothienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 1-, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, and 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl.
  • hydrocarbon-heteroatom chain refers to a hydrocarbon chain wherein one or more carbon atoms are replaced with a heteroatom.
  • heteroalkylene refers to an alkylene radical as defined above that includes one or more heteroatoms such as oxygen, sulfur, or nitrogen (with valence completed by hydrogen or oxygen) in the carbon chain or termi n ati n g the carbon chai n .
  • lower alkoxy and “lower thioalkoxy” as used herein refers to O- alkyl or S-alkyl of from 1 to 6 carbon atoms as defined above for “lower alkyl.”
  • aryl refers to an aromatic ring which is unsubstituted or optionally substituted by 1 to 4 substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, halogen, nitro, cyano -OH, -SH, -CF 3 , -CO 2 H, -CO 2 CrC 6 alkyl, -(CH 2 ) 0 .
  • R' and R" are independently alkyl, akenyl, alkynyl, aryl, or joined together to form a 4 to 7 member ring.
  • Examples include, but are not limited to, phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2- methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-methoxyphenyl, 3- methoxyphenyl, 4-methoxyphenyl, 2-chloro-3-methylphenyl, 2-chloro-4- methylphenyl, 2-chloro-5-methylphenyl, 3-chloro-2-methylphenyl, 3-chloro-4- methylphenyl, 4-chloro-2-methylphenyl, 4-chloro-3-methylphenyl, 5-chloro-2- methylphenyl, 2,3-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2,3- di methylphenyl, 3,4-dimethylphenyl, and the like.
  • heteroaryl means an aromatic ring containing one or more heteroatoms.
  • the heteroaryl is optionally substituted with one or more groups enumerated for aryl.
  • heteroaryl include, but are not limited to, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazoyl, pyrazinyl, oxazolyl, thiazolyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl, and quinazolinyl, and the like.
  • cycloalkenyl means a cycloalkyl group having one or more carbon-carbon double. Example includes cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclobutadiene, cyclopentadiene, and the like.
  • patient means all mammals including humans. Examples of patients include humans, cows, dogs, cats, goats, sheep, pigs, and rabbits.
  • a “therapeutically effective amount” is an amount of a compound of the present invention that when administered to a patient ameliorates a symptom of dyslipidemia, non-insulin dependent diabetes mellitus, obesity, hyperglycemia, hypercholesteremia, hyperlipidemia, atherosclerosis, hypertriglyceridemia, or hyperinsulinemia.
  • a pharmaceutically acceptable salt refers to the relatively non- toxic, inorganic and organic base or acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free form with a suitable organic or inorganic base or acid and isolating the salt thus formed.
  • Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts, and the like.
  • alkali and alkaline earth metals such as sodium, lithium, potassium, calcium, magnesium, and the like
  • non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.
  • the free base form may be regenerated by contacting the salt form with a base. While the free base may differ from the salt form in terms of physical properties, such as solubility, the salts are equivalent to their respective free bases for the pu ⁇ oses of the present invention.
  • the symbol " w s r » indicates a point of attachment.
  • the present invention provides compounds capable of modulating PPAR activity.
  • Compounds of the present invention are described by Formula I:
  • W is O, S, CR 5 R 6 , -(CH 2 ) p -cycloalkylene, or -(CH 2 ) p -heterocycloalkylene;
  • X° and X 1 are independently O or S;
  • Ar 1 is a unsubstituted or substituted aryl or heteroaryl
  • R 1 , R 2 , R 3 , and R 4 are independently hydrogen, lower alkyl, lower alkoxy, haloalkyl,-O-(CH 2 ) p CF 3 , halogen, nitro, cyano, -OH, -SH, -CF 3 , -S(O) p alkyl, S(O) p aryl, -(CH 2 ) m OR 7 , -(CH 2 ) m NR 8 R 9 , -COR 7 , -CO 2 H, -CO 2 R 7 , or -NR 8 R 9 ;
  • R 5 and R 6 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl, or joined together to form a 3 to 7 member cycloalkyl or cycloalkenyl;
  • R 7 is independently hydrogen, alkyl, alkenyl, alkynyl, or aryl
  • R 8 and R 9 are independently hydrogen, alkyl, alkenyl, alkynyl, -COalkyl, - COaryl, cycloalkyl, -CO 2 alkyl, -CO 2 aryl, -SO 2 alkyl, -SO 2 aryl, or joined together to form a 4 to 7 member ring having 1 to 3 heteroatoms;
  • R and R are not hydrogen.
  • Examples of compounds of Formula I include those where W is O, Ar is substituted aryl, and n is i .
  • compounds of Formula I where W is O, Ar 1 is substituted aryl, and n is 1 include those where Ar 1 is 4-trifluoromethylphenyl.
  • R 1 , R 2 , R 3 , and R 4 are independently hydrogen, lower alkyl, lower alkoxy, -(CH 2 ) m NR 8 R 9 , or - (CH 2 ) m OR 7 ; where R 7 is alkyl, R 8 and R 9 are independently hydrogen, alkyl, or- COalkyl.
  • R 1 , R 2 , R 3 , and R 4 are the following combinations shown in Table 1 below, provided that R 1 , R' R 3 , and R 4 are not each hydrogen when W is O.
  • R 2 is hydrogen
  • R 1 , R 3 , and R 4 are independently lower alkyl, lower alkoxy, haloalkyl,-O- (CH 2 ) P CF 3 , halogen, nitro, cyano, -OH, -SH, -CF 3 , -S(O) p alkyl, S(O) p aryl, - (CH 2 ) m OR 7 , -(CH 2 ) m NR 8 R 9 , -COR 7 , -CO 2 H, -CO 2 R 7 , or -NR 8 R 9 ;
  • R 7 is hydrogen, alkyl, alkenyl, alkynyl, or aryl; and
  • R 8 and R 9 are independently hydrogen, alkyl, alkenyl, alkynyl, -COalkyl, -COaryl, cycloalkyl, -CO 2 alkyl, -CO 2 aryl,
  • compounds of Formula I also include those where R 2 and R are both hydrogen.
  • compounds of Formula I where R and R are hydrogen include those where R 2 and R 3 are hydrogen, and R 1 and R 4 are lower alkyl, such as methyl, ethyl, isopropyl, n-propyl, t-butyl, n-butyl, and isobutyl, or lower alkoxy, such as methoxy, ethoxy, isopropoxy, n-propoxy, t-butoxy, n-butoxy, and isobutoxy.
  • More specific examples of compounds of Formula I where R and R are hydrogen include those where R 2 and R 3 are hydrogen, R 1 is lower alkyl, and R 4 is lower alkoxy.
  • R 1 and R 1 ' are independently fluorine, phenyl or pyrrolyl;
  • Additional examples of compounds of Formula I include those where W is CR 5 R 6 , -(CH 2 ) p -cycloalkylene, or -(CH 2 ) p -heterocycloalkylene, R 5 and R 6 are joined together to form a 3 to 7 member cycloalkyl or cycloalkenyl ring, and p is 0 to 2.
  • compounds of Formula I where W is CR 5 R , -(CH 2 ) p -cycloalkylene, or - (CH 2 ) p -heterocycloalkylene include those where W is or
  • compounds of Formula I where W is CR 5 R 6 , -(CH 2 ) P - cycloalkylene, or -(CH 2 ) p -heterocycloalkylene include those where X° and X 1 are S.
  • p cycloalkylene, or -(CH 2 ) p -heterocycloalkylene include those where Ar j is 4- trifluoromethylphenyl.
  • compounds of Formula I where W is CR 5 R , -(CH 2 ) P - cycloalkylene, or -(CH 2 ) p -heterocycloalkylene include those where R 1 , R 2 , R 3 , and R 4 are independently hydrogen, lower alkyl, lower alkoxy, halogen, -CF 3 , -(CH 2 ) m OR 7 , or -(CH 2 ) m NR 8 R 9 ; R 7 is hydrogen, or alkyl; and R 8 and R 9 are independently hydrogen, alkyl, or -COalkyl.
  • Such compounds include those where R , R , R , R , and R 4 are independently hydrogen, methyl, ethyl, isopropyl, n-propyl, t-butyl, n-butyl, or isobutyl, methoxy, ethoxy, isopropoxy, n-propoxy, t-butoxy, n-butoxy, isobutoxy, - (CH 2 )-OCH 3 , or -NH-COCH 3 .
  • Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R or S configuration.
  • the present invention includes all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof. Stereoisomers may be obtained, if desired, by methods known in the art as, for example, the separation of stereoisomers by chiral chromatographic columns. Additionally, the compounds of the present invention may exist as geometric isomers.
  • the present invention includes all cis, trans, syn, anti,
  • E Electronic Data
  • compounds may exist as tautomers. All tautomers are included within Formula I and are provided by this invention.
  • the compounds of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
  • the solvated forms are considered equivalent to the unsolvated forms for the pu ⁇ oses of the present invention.
  • the present invention includes all pharmaceutically acceptable, non-toxic esters of the compounds of Formula I.
  • esters include C ⁇ -C 6 alkyl esters wherein the alkyl group is a straight or branched chain.
  • Acceptable esters also include C 5 -C 7 cycloalkyl esters as well as arylalkyl esters such as, but not limited to benzyl.
  • C ⁇ -C alkyl esters are preferred.
  • Esters of the compounds of the present invention may be prepared according to conventional methods.
  • the compounds of the present invention are suitable to be administered to a patient for the treatment, control, or prevention of non-insulin dependent diabetes mellitus, hypercholesteremia, hyperlipidemia, obesity, hyperglycemia, hyperlipidemia, atherosclerosis, hypertriglyceridemia, and hyperinsulinemia. Accordingly, the compounds may be administered to a patient alone or as part of a composition that contains other components such as excipients, diluents, and carriers, all of which are well-known in the art.
  • compositions can be administered to humans and/or animals either orally, rectally, parenterally (intravenously, intramuscularly, or subcutaneously), intracisternally, intravaginally, intraperitoneally, intravesically, locally (powders, ointments, or drops), or as a buccal or nasal spray.
  • compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
  • compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents.
  • adjuvants such as preserving, wetting, emulsifying, and dispensing agents.
  • Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • isotonic agents for example sugars, sodium chloride, and the like.
  • Prolonged abso ⁇ tion of the injectable pharmaceutical form can be brought about by the use of agents delaying abso ⁇ tion, for example, aluminum monostearate and gelatin.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or
  • fillers or extenders as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid;
  • binders as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia;
  • humectants as for example, glycerol;
  • disintegrating agents as for example, agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate;
  • solution retarders as for example paraffin;
  • abso ⁇ tion accelerators as for example, quaternary ammonium compounds
  • the dosage forms may also comprise buffering agents.
  • wetting agents as for example, cetyl alcohol and glycerol monostearate
  • adsorbents as for example, kaolin and bentonite
  • lubricants as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof.
  • the dosage forms may also comprise buffering agents.
  • compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar, as well as high molecular weight polyethyleneglycols, and the like.
  • Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others well-known in the art. They may contain opacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions which can be used are polymeric substances and waxes. The active compounds can also be in micro- encapsulated form, if appropriate, with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1 ,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols and fatty acid esters of sorbitan or mixtures of these substances, and the like.
  • inert diluents commonly used in the art, such as water or other solvents, solub
  • composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Suspensions in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar- agar and tragacanth, or mixtures of these substances, and the like.
  • suspending agents as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar- agar and tragacanth, or mixtures of these substances, and the like.
  • compositions for rectal administrations are preferably suppositories which can be prepared by mixing the compounds of the present invention with suitable non- irritating excipients or carriers such as cocoa butter, polyethyleneglycol, or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.
  • suitable non- irritating excipients or carriers such as cocoa butter, polyethyleneglycol, or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.
  • Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays, and inhalants.
  • the active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required.
  • Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.
  • the compounds of the present invention can be administered to a patient at dosage levels in the range of about 0.1 to about 2,000 mg per day.
  • dosage levels in the range of about 0.1 to about 2,000 mg per day.
  • a dosage in the range of about 0.01 to about 10 mg per kilogram of body weight per day is preferable.
  • the specific dosage used can vary.
  • the dosage can depend on a numbers of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well-known to those skilled in the art.
  • the present invention contains compounds that can be synthesized in a number of ways familiar to one skilled in organic synthesis.
  • the compounds disclosed herein can be synthesized according to the methods described below and in the examples, along with methods typically utilized by a synthetic chemist, and combinations or variations of those methods, which are generally known to one skilled in the art of synthetic chemistry.
  • the synthetic route of compounds in the present invention is not limited to the methods outlined below. It is assumed one skilled in the art will be able to use the schemes outlined below to synthesize compounds claimed in this invention.
  • Individual compounds may require manipulation of the conditions in order to accommodate various functional groups. A variety of protecting groups generally known to one skilled in the art may be required. Purification, if necessary, can be accomplished on a silica gel column eluted with the appropriate organic solvent system. Also, reverse phase HPLC or recrystallization may be employed.
  • the compounds or Formula I can be prepared by reacting: in a solvent in the presence of a base such as cesium carbonate, with the aryl halide: wherein:
  • W, Y, n, R 1 , R 2 , R 3 , R 4 , X°, X 1 and Ar 1 are the same as defined above for Formula I;
  • R 12 is a lower alkyl; and X is a halogen.
  • aryl halides include, for example, 5-chloromethyl-4- methyl-2-(4-trifluoromethyl-phenyl)-thiazole.
  • the compounds of Formula I can be prepared using the synthetic route outlined in Scheme 1 when W is O or S and X° is S.
  • compounds of the general formula A are thiocyanated with a mixture of bromine and sodium thiocyanate to give compounds of the general formula B.
  • compounds of the general formula B are then alkylated with the haloester C to give compounds of the general formula D.
  • a useful haloester C is the corresponding bromoester.
  • Compounds of the general formula E are then prepared by reduction of D with dithiothreitol in methanol.
  • Compounds of the general formula E are then alkylated with the halide compound IB to form compound F.
  • Suitable halide compounds IB include, for example, 5-chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole.
  • Compounds of the general formula F are then saponified with LiOH in THF to give the final compound G.
  • W, Y, R 1 , R 2 , R 3 , and R 4 are the same as defined above for Formula I above;
  • X is a halogen.
  • Compound G corresponds to compounds described by Formula I above when X° is S.
  • compounds of Formula I can be prepared using the synthetic route outlined in Scheme 2 when X° is S.
  • compounds of the general formula H are debenzylated and then reacted with 2-chloro-N,N- dimethyl-thioacetamide to form compound J.
  • a useful method for stepl is reaction with hydrogen gas in the presence of carbon activated palladium.
  • Compound J is then heated followed by saponification to form compound E.
  • Compounds of the general formula E are then alkylated with the halide compound IB to form compound F.
  • Suitable halide compounds IB include, for example, 5-chloromethyl-4-methyl-2- (4-trifluoromethyl-phenyl)-thiazole.
  • compounds of Formula I can be prepared using the synthetic route outlined in Scheme 3.
  • compounds of the general formula K are converted to the ester L.
  • a useful method includes reacting compound K with an alcohol in the presence of an acid such as hydrochloric acid, although any compatible method for esterification may be used.
  • Ester L is then reacted with cholorsulfonic acid to form compound M.
  • Compound M is then reduced to form compound E.
  • Compounds of the general formula E are then alkylated with the halide compound IB to form compound F.
  • Suitable halide compounds IB include, for example, 5-chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole.
  • 2B was prepared from 2A in a similar manner as described for compound 3A to give, after purification by flash column chromatography (gradient elution: 100% hexanes to 20% EtOAc/hexane) and then recrytalisation from CHCl 3 /hexanes, 0.8 g (29%) of the title compound as a single regioisomer.
  • 2D was prepared from 2C in a similar manner as described for compound 3C to give, after purification by flash column chromatography (gradient elution: 100% hexanes to 30% EtOAc/hexanes), 0.3 g (32%) of the title compound.
  • Compound 7C was prepared from compound 7B in a similar manner as described for compound 3C to give, after purification by flash column chromatography (gradient elution: 100% hexanes to 30% EtOAc/hexanes), 0.38 g (21 %) of the title compound. 400 MHz ⁇ NMR (DMSO-d 6 ) ⁇ 6.66 (s, 2H), 4.68 (s, 2H), 4.20 (s, IH), 3.63 (s, 3H), 2.23 (s, 6H).
  • Compound 13A was made following the procedure in Example 12A, by replacing 2- Phenyl-cyclopropanecarboxylic acid with compound 1 -Phenyl- cyclopropanecarboxylic acid. Compound 13A was prepared in quantitative yield. MS: 177 (M+1) + .
  • Compound 14A was made following the procedure in Example 12A, by replacing 2- Phenyl-cyclopropanecarboxylic acid with 1-Phenyl-cyclopentanecarboxylic acid. Compound 14A was prepared in quantitative yield. MS: 205 (M+l) + .
  • Compound 15A was prepared by hydrogenation of the corresponding crotonate catalyzed by Pd/C (10%) in 93% yield. MS: 221 (M+l) + .
  • Compound 16A is commercially available from Aldrich of Milwaukee, Wisconsin.
  • Compound 16 was prepared by treating the ester with concentrated HBr in 17% yield.
  • Methane sulfonyl chloride was added to a stirred solution of compound 18B dissolved in CH 2 C1 2 and triethyl amine at 0°C. The mixture was stirred at RT for 4 hr. It was then diluted with CH 2 C1 2 and washed with 1 x sat. NFLC1, 1 x brine, dried (MgSO ) and the solvent removed in vacuo to give 2.68 g (88%) of the methanesulfonated compound.
  • the methanesulfonated intermediate obtained from above was dissolved in DMSO and added with sodium cyanide. The mixture was heated at 100°C overnight. After cooling down to RT, the reaction mixture was diluted with water and layered with ether. The layers were separated and the aqueous layer extracted with ether. The combined organics were dried over MgSO and condensed to give the crude product as an oil. It was purified by silica gel chromatography eluted with 10% EtOAc/ ⁇ exanes to afford the desired compound 18C as a clear oil (0.26 g, 26%). MS: 160 (M+1 ) + .
  • 19C 19C was prepared analogously to compound 12C. Used as unpurified oil. MS: 271 (M+l ) + .
  • Compound 23A was prepared according to the method of example IF utilizing 3-(4- hydroxy-phenyl)-2-phenylpropionic acid methyl ester. MS: 512 (M+l) + .
  • Compound 23 was prepared according to the method of example 1 utilizing compound 23A. MS: 498 (M+1 ) + .
  • 26A A mixture of 5-fluoro-2-methylphenylamine in concentrated sulfuric acid and water was heated until a clear solution was obtained, then cooled to 0 °C, a solution of sodium nitrite in water was added dropwise over 15 minutes, then poured into boiled saturated copper sulfate solution and heated for 15 minutes, cooled and extracted with ethyl acetate washed with water, brine, dried over anhydrous sodium sulfate, and concentrated to give 26A in good purity. 400 MHz ⁇ NMR (CDC1 ) ⁇ 7.05 (t, IH), 6.56 (m, 2H), 4.92 (s, IH), 2.19 (s, 3H).
  • 29D To a solution of 29C in THF and N,N'-dimethylethyleneurea under nitrogen atmosphere was added DL-methylproline hydrochloride. The resulting mixture was stirred until clear , then glacial acetic acid was added dropwise followed by sodium triacetoxyborohydride in small portions over 30 min. The reaction mixture was stirred 16h, quenched with water, and extracted with EtOAc. The combined extracts were washed with brine. The organic phase was dried over magnesium sulfate and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 20% EtOAc/Hexane) to give 29D as a yellow solid.
  • Compound 33A was prepared as follows. Chlorosulfonic acid was cooled to 0 °C. Then (4-Phenyl-cyclohexyl)-acetic acid ethyl ester was added over 30 min. The - I l l-
  • the compounds of the present invention have demonstrated PPAR modulating activity in the standard assays commonly employed by those skilled in the art. Accordingly, such compounds and formulations comprising such compounds are useful for treating, preventing or controlling hypercholesterolemia and hyperlipidemia.
  • Test A Transient transfections assay using the HepG2 hepatoma cell line.
  • HepG2 cells were transiently transfected with an expression plasmids encoding hPPAR ⁇ , hPPAR ⁇ or mPPAR ⁇ chimeric receptors and a reporter containing the yeast upstream activating sequence (UAS) upstream of the viral E1B promoter controlling a luciferase reporter gene.
  • UAS yeast upstream activating sequence
  • the plasmid pRSV ⁇ -gal was used to control for transfection efficiency.
  • HepG2 cells were grown in DMEM supplemented with 10%FBS and l ⁇ M non-essential amino acid. On the first day, cells were split into 100mm dishes at 2.5x 10 6 /dish and incubated overnight at
  • the cells were transiently transfected with plasmid DNA encoding a chimeric receptor, the luciferase reporter gene; and ⁇ -gal.
  • plasmid DNA encoding a chimeric receptor, the luciferase reporter gene; and ⁇ -gal.
  • 15 ⁇ g of lucifease reporter (PG5Elb) DNA, 15 ⁇ g of Gal4-PPAR chimeric receptor DNA, and 1.5 ⁇ g of ⁇ -gal plasmid DNA were mixed with 1.4ml of opti-MEM in the tube.
  • 28 ⁇ l of LipoFectamine-2000 reagent was added to 1.4ml of opti-MEM in the tube, and incubate for 5 min at RT.
  • the diluted Lipofectamine-2000 reagent was combined with the DNA mixture, and incubate for 20 min at RT. After fresh medium was added to each 100mm dish of cells, 2.8ml of Lipofectamine2000- DNA mixture was added dropwise to the 100mm dish containing 14ml of medium, and incubate 37°C overnight. On day three cells were trypsinized off thel 00 mm dishes and re-plated on 96 well plates. Cells were plated at 2.5x10 cells per well in 150 ⁇ l of media and 50 ⁇ l of compound diluted by media was added. The test compounds added were in the range from 50 ⁇ M to 50pM. After addition of compounds, the plates were incubated at 37C° for 24 hours.
  • mice transgenic for human apoAl, were purchased from Jackson laboratories. All animals were allowed normal chow (Ralston-Purina) and water ad libitum in temperature controlled rooms, under a 12-h light, 12-h dark cycle beginning with lights on at 6 AM. During the treatment phase of the study the mice were dosed daily between 6 and 9 AM by oral gavage using a suspension vehicle of 1.5% carboxymethylcellulose plus 0.2 percent Tween-20 (CMC/Tween) containing the specified compounds. Control animals received vehicle alone. Vehicle volume represented 0.25 percent of body weight. Under anesthesia, tail blood was obtained weekly in the morning at the indicated days of study. At termination, tissue samples (liver, intestine, fat, and muscle) were taken to study effects on genes effecting lipid metabolism. Each of the compounds of the present invention that were tested effected a significant increase in HDL over the values observe for the control animals. Furthermore, these compounds resulted in triglyceride levelswhich were lower than 16-
  • the compounds of the present invention exhibited a 61 to 123 mg/dL increase in HDL compared to a 44 mg/dL increase for the controls at the end of the study (day 16). Similarly, compounds of the present invention exhibited an increase on average for the HDL to (LDL + VLDL) ratio. This ratio was 14 to 18.3 at the beginning of the study. At the end of the study this ratio was found to be from 1 1.9 to 83.9. (Controls dropped from 15.5 to 1 1.9)
  • the compounds of the present invention can be administered alone or in combination with one or more therapeutic agents. These include, for example, other agents for treating, preventing or controlling hypercholesteremia, hyperlipidemia, obesity, hyperglycemia, hypercholesteremia, hyperlipidemia, atherosclerosis, hypertriglyceridemia, and hyperinsulinemia.
  • the compounds are thus well suited to formulation for convenient administration to mammals for the prevention and treatment of such disorders.
  • the ingredients are blended to uniformity and pressed into a tablet that is well suited for oral administration to a patient.
  • the ingredients are combined and milled to afford material suitable for filling hard gelatin capsules administered to a patient.

Abstract

This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses methods for making the disclosed compounds.

Description

THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY
FIELD OF THE INVENTION
The present invention relates to compounds and pharmaceutical formulations that can be used to treat conditions mediated by nuclear hormone receptors, more specifically, to compounds and pharmaceutical formulations that modulate PPAR activity.
BACKGROUND OF THE INVENTION
Hypercholesterolemia, hyperlipidemia, and diabetes are well recognized risk factors in the onset of atherosclerosis and coronary heart disease. Hypercholesterolemia and hyperlipidemia are characterized by excessively high levels of blood cholesterol and lipids. The blood cholesterol pool is generally dependent on dietary uptake of cholesterol from the intestine and biosynthesis of cholesterol throughout the body, especially the liver. The majority of cholesterol in plasma is carried on apolipoprotein B-containing lipoproteins, such as low-density lipoproteins (LDL) and very-low-density lipoproteins (NLDL). The risk of coronary artery disease in man increases when LDL and VLDL levels increase. Conversely, high levels of cholesterol carried in high-density lipoproteins (HDL) is protective against coronary artery disease (Am. J. Med., 1977;62:707-714).
The statins represent perhaps the most important class of lipid-lowering drugs.
These compounds inhibit HMG-CoA reductase which is implicated in the rate- limiting step in cellular cholesterol biosynthesis. Representative statins include atorvastatin, lovastatin, pravastatin, and simvastatin. The effectiveness of these compounds depends on LDL receptor regulation. Other important antilipidemia drugs include fibrates such as gemfibril and clofibrate, bile acid sequestrants such as cholestyramine and colestipol, probucol, and nicotinic acid analogs.
To date, a number of oral antidiabetic agents have been developed. The most commonly used hypoglygemic drugs are the sulfonylureas. Sulfonylureas are generally used to stimulate insulin. The biguanide metformin is generally used to improve insulin sensitivity and to decrease hepatic glucose output. Acarbose is used to limit postprandial hyperglycemia. Thiazolidine 2,4 diones are used to enhance insulin action without increasing insulin secretion.
Peroxisome Proliferator Activation Receptors (PPAR) are implicated in a number of biological processes and disease states including hypercholesterolemia, hyperlipidemia, and diabetes. PPARs are members of the nuclear receptor superfamily of transcription factors that includes steroid, thyroid, and vitamin D receptors. They play a role in controlling expression of proteins that regulate lipid metabolism. Furthermore, the PPARs are activated by fatty acids and fatty acid metabolites. There are three PPAR subtypes PPAR α, PPAR β (also referred to as PPAR δ), and PPAR γ. Each receptor shows a different pattern of tissue expression, and differences in activation by structurally diverse compounds. PPAR γ, for instance, is expressed most abundantly in adipose tissue and at lower levels in skeletal muscle, heart, liver, intestine, kidney, vascular endothelial and smooth muscle cells as well as macrophages. PPAR receptors are associated with regulation of insulin sensitivity and blood glucose levels, macrophage differentiation, inflammatory response, and cell differentiation. Accordingly, PPARs have been associated with obesity, diabetes, carcinogenesis, hyperplasia, atherosclerosis, hyperlipidemia, and hypercholesterolemia.
In addition, PPARα agonists lower plasma triglycerides and LDL cholesterol and are therefore useful in treating hypertriglyceridemia, hyperlipidemia and obesity. PPAR γ is associated with the development of non-insulin-dependent diabetes mellitus (NIDDM), hypertension, coronary artery disease, hyperlipidemia and certain malignancies. Finally, activation of PPAR β has been demonstrated to increase HDL levels. (Leibowitz, WO97/28149, Aug. 1997.) More recently, a PPAR β selective agonist was reported to have shown a dose-related increase in serum HDL-C and decrease in LDL-C and VLDL-TG in insulin-resistant middle aged rhesus monkeys. (W. R. Oliver et al., PNAS, v. 98, pp. 5306-531 1 , 2001)
Antilipidemic and antidiabetic agents are still considered to have non-uniform effectiveness. The effectivieness of antidiabetic and antilipidemic therapies is limited, in part because of poor patient compliance due to unacceptable side effects. These side effects include diarrhea and gastrointestinal discomfort, and in the case of anti diabetics, edema, hypoglycemia and hepatoxicity. Furthermore, each type of drug does not work equally well in all patients.
For the reasons set forth above, there is a need for novel antilipidemic and antidiabetic agents that can be used alone or in combination. Furthermore, activation of PPARβ alone or in combination with the simultaneous activation of PPAR α and/or PPAR γ may be desirable in formulating a treatment for hyperlipidemia in which HDL is increased and LDL lowered.
SUMMARY OF THE INVENTION The present invention provides compounds capable of modulating PPAR activity. Compounds of the present invention are described by Formula I:
Figure imgf000005_0001
or a pharmaceutically acceptable salt thereof, where:
W is O, S, CR ..V R.6°, -(CH2)p-cycloalkylene, or -(CH2)p-heterocycloalkylene;
X° and X1 are independently O or S;
Ar1 is a unsubstituted or substituted aryl or heteroaryl;
R1, R2, R3, and R4 are hydrogen, lower alkyl, lower alkoxy, haloalkyl,-O- (CH2)PCF3, halogen, nitro, cyano, -OH, -SH, -CF3, -S(O)palkyl, S(O)paryl, - (CH2)mOR7, -(CH2)mNR8R9, -COR7, -CO2H, -CO2R7, or -NR8R9;
R5 and R6 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl, or joined together to form a 3 to 7 member cycloalkyl or cycloalkenyl;
R7 is independently hydrogen, alkyl, alkenyl, alkynyl, or aryl;
R8 and R9 are each independently hydrogen, alkyl, alkenyl, alkynyl, -COalkyl, -COaryl, cycloalkyl, -CO2alkyl, -CO2aryl, -SO alkyl, -SO2aryl, or joined together to form a 4 to 7 member ring having 1 to 3 heteroatoms;
R10 and Rπ are independently hydrogen, halo, aryl, or hereroaryl; m is 0 to 5; n is 0 to 5; and p is 0 to 2; with the following provisos: that when W is O, n = 1 , and R1 is hydrogen, R2 and R4 are not hydrogen or R2 and R3 are not hydrogen; that when W is O, n = 1 , and R is hydrogen, R and R are not hydrogen or R1 and R4 are not hydrogen; that when W is O, n = 1, and R' is hydrogen, R1 and R are not hydrogen or R2 and R4 are not hydrogen; and that when W is O, n = 1 , and R4 is hydrogen, R1 and R3 are not hydrogen or
R2 and R3 are not hydrogen.
In one embodiment of the present invention a pharmaceutical composition comprising a compound of Formula I and one or more pharmaceutically acceptable carriers, diluents, or excipients is provided. In one embodiment of the present invention a method of treating, preventing or controlling hypercholesteremia and hyperlipidemia in a mammal is provided. The method comprises administering to the mammal in need thereof a therapeutically effective amount of the compounds of the present invention.
In another embodiment of the present invention a method for treating, preventing, or controlling obesity is provided.
In another embodiment of the present invention a method for treating, preventing, or controlling hyperglycemia is provided.
In another embodiment of the present invention a method for treating, preventing, or controlling atherosclerosis is provided. In another embodiment of the present invention a method for treating, preventing, or controlling hypertriglyceridemia is provided.
In another embodiment of the present invention a method for treating, preventing, or controlling hyperinsulinemia is provided. In another embodiment of the present invention a method for treating, preventing, or controlling diabetes is provided.
For each disease state treatable, preventable, or controllable by the method of the present invention, a therapeutically effective amount of the compounds of the present invention are administered to the mammal in need thereof.
In yet another embodiment of the present invention, a method for preparing compounds of Formula I is provided.
DETAILED DESCRIPTION OF THE INVENTION
The following definitions are used, unless otherwise described: alkyl, alkoxy, alkenyl, alkynyl, etc. denote both straight and branched groups; but reference to an individual radical such as "propyl" embraces only the straight chain radical, a branched chain isomer such as "isopropyl" being specifically referred to.
The term "alkyl" as used herein refers to a straight or branched hydrocarbon of from 1 to 1 1 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, and the like. The alkyl group can also be substituted with one or more of the substituents selected from lower alkoxy, lower thioalkoxy, -O(CH2)o-2CF3, halogen, nitro, cyano, =O, =S, -OH, -SH, CF3, -OCF3, -CO2H, -CO2C,-C6 alkyl, -NH2, -NHC,-C6 alkyl, -CONR'R", or -N(Cι-C6alkyl)2 where R' and R" are independently alkyl, akenyl, alkynyl, aryl, or joined together to form a 4 to 7 member ring. Useful alkyl groups have from 1 to 6 carbon atoms (Cι-C6 alkyl).
The term "lower alkyl" as used herein refers to a subset of alkyl which means a straight or branched hydrocarbon radical having from 1 to 6 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, and the like. Optionally, herein lower alkyl is referred to as "Ci-Cβalkyl."
The term "haloalkyi" as used herein refers to a lower alkyl radical, as defined above, bearing at least one halogen substituent, for example, chloromethyl, fluoroethyl, trifluoromethyl, or 1 ,1 ,1-trifluoroethyl and the like. Haloalkyi can also include perfluoroalkyl wherein all hydrogens of a loweralkyl group are replaced with fluorine atoms.
The term "alkenyl" means a straight or branched unsaturated hydrocarbon radical having from 2 to 12 carbon atoms and includes, for example, ethenyl, 1- propenyl, 2-propenyl, 1 -butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 3-methyl-3- butenyl, ] -hexenyl, 2-hexenyl, 3-hexenyl, 3-heptenyl, 1-octenyl, 1 -nonenyl, 1- decenyl, 1 -undecenyl, 1-dodecenyl, and the like.
The term "alkynyl" means a straight or branched hydrocarbon radical having from 2 to 12 carbon atoms having at least one triple bond and includes, for example, 1-propynyl, 1 -butynyl, 3-butynyl, 1 -pentynyl, 3-pentynyl, 3-methyl-3-butynyl, 1- hexynyl, 3-hexynyl, 3-heptynyl, 1-octynyl, 1-nonynyl, 1-decynyl, 1 -undecynyl, 1- dodecynyl, and the like.
The term "alkylene" as used herein refers to a divalent group derived from a straight or branched chain saturated hydrocarbon having from 1 to 10 carbon atoms by the removal of two hydrogen atoms, for example methylene, 1 ,2-ethylene, 1,1- ethylene, 1 ,3-propylene, 2,2- dimethylpropylene, and the like. The alkylene groups of this invention can be optionally substituted. The alkylene group can also be substituted with one or more of the substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, -O(CH2)o-2CF3, halogen, nitro, cyano, =O, =S, -OH, -SH, -CF3, -CO2H, -CO2d-C6 alkyl, -NH2, -NHC,-C6 alkyl, -CONR'R", or -N(Cι-C6alkyl)2 where R' and R" are independently alkyl, akenyl, alkynyl, aryl, or joined together to form a 4 to 7 member ring. Useful alkylene groups have from 1 to 6 carbon atoms (Cι-C6 alkylene).
The term "cycloalkylene" as used herein refers to a divalent group derived from a cyclic saturated hydrocarbon having from 3 to 8 carbon atoms by the removal of two hydrogen atoms. The cycloalkylene groups of this invention can be optionally substituted. The cycloalkylene group can also be substituted with one or more of the substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, -O(CH2)0. 2CF3, halogen, nitro, cyano, =O, =S, -OH, -SH, -OCF3, -CO2H, -CO2Cι-C6 alkyl, -NH2, -NHCι-C6 alkyl, -CONR'R", or -N(C,-C6alkyl)2 where R' and R" are independently alkyl, akenyl, alkynyl, aryl, or joined together to form a 4 to 7 member ring. Useful cycloalkylene groups have from 3 to 6 carbon atoms (C3-C6 alkyl).
The term "halogen" includes chlorine, fluorine, bromine, and iodine.
The term "heteroatom" as used herein represents oxygen, nitrogen, or sulfur (O, N, or S) as well as sulfoxyl or sulfonyl (SO or SO2) unless otherwise indicated.
The term "heterocycloalkylene" as used herein, refers to a cycloalkylene group that includes one or more heteroatoms such as oxygen, sulfur, or nitrogen.
The term "hydrocarbon chain" as used herein refers to a straight hydrocarbon of from 2 to 6 carbon atoms. The hydrocarbon chain is optionally substituted with one or more substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, - O(CH2)0.2CF3, halogen, nitro, cyano, =O, =S, -OH, -SH, -CF3, -CO2H, -CO2(C C6 alkyl), -NH2, -NHCrC6 alkyl, -CONR'R", or -N(Cι-C6alkyl)2 where R' and R" are independently alkyl, akenyl, alkynyl, aryl, or joined together to form a 4 to 7 member ring. The term "heterocycle" means a saturated or unsaturated mono- or polycyclic (i.e. bicyclic) ring incoφorating one or more (i.e. 1-4) heteroatoms selected from N, O, and S. It is understood that a heterocycle is optionally substituted with -OH, - O(alkyl), SH, S(alkyl), amine, halogen, acid, ester, amide, amidine, alkyl ketone, aldehyde, nitrile, fluoroalkyl, nitro, sulphone, sulfoxide or C|-6 alkyl. Examples of suitable monocyclic heterocycles include, but are not limited to substituted or unsubstituted thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazoiyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, piperidinyl, pyrrolidinyl, piperazinyl, azetidinyl, aziridinyl, moφholinyl, thietanyl, oxetaryl. Examples of monocyclic diheterocycles include, but are not limited to, 1-, 2- , 4-, or 5-imidazolyl, 1-, 3-, 4-, or 5-pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5- isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5-isoxazolyl, 1, 3-, or 5-triazolyl, 1-, 2-, or 3-tetrazolyl, 2-pyrazinyl, 2-, 4-, or 5-pyrimidinyl, 1- or 2-piperazinyl, 2-, 3-, or 4- moφholinyl. Examples of suitable bicyclic heterocycles include, but are not limited to indolizinyl, isoindolyl, benzofuranyl, benzothienyl, benzoxazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, quinazolinyl, 1-, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 1-, 2-, 3-, 5-, 6-, 7-, or 8-indolizinyl, 1-, 2-, 3-, 4-, 5-, 6-, or 7-isoindolyl, 2-, 3-, 4-, 5-, 6-, or 7- benzothienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 1-, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, and 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl.
The term "hydrocarbon-heteroatom chain" as used herein refers to a hydrocarbon chain wherein one or more carbon atoms are replaced with a heteroatom. The hydrocarbon-heteroatom chain is optionally substituted with one or more substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, -O(CH2)0- 2CF3, halogen, nitro, cyano, =O, =S, -OH, -SH, -CF3, -CO2H, -CO2Cι-C6 alkyl, -NH2, -NHCι-C6 alkyl, -CONR'R", or -N(Cι-C6alkyl)2 where R' and R" are independently alkyl, akenyl, alkynyl, aryl, or joined together to form a 4 to 7 member ring. The term "heteroalkylene" as used herein, refers to an alkylene radical as defined above that includes one or more heteroatoms such as oxygen, sulfur, or nitrogen (with valence completed by hydrogen or oxygen) in the carbon chain or termi n ati n g the carbon chai n .
The terms "lower alkoxy" and "lower thioalkoxy" as used herein refers to O- alkyl or S-alkyl of from 1 to 6 carbon atoms as defined above for "lower alkyl."
The term "aryl" as used herein refers to an aromatic ring which is unsubstituted or optionally substituted by 1 to 4 substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, halogen, nitro, cyano -OH, -SH, -CF3, -CO2H, -CO2CrC6 alkyl, -(CH2)0.2CF3, -NH2, -NHC,-C6 alkyl, -SO2alkyl, -SO2NH2, - CONR'R", or -N(C,-C6alkyl)2 where R' and R" are independently alkyl, akenyl, alkynyl, aryl, or joined together to form a 4 to 7 member ring. Examples include, but are not limited to, phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2- methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-methoxyphenyl, 3- methoxyphenyl, 4-methoxyphenyl, 2-chloro-3-methylphenyl, 2-chloro-4- methylphenyl, 2-chloro-5-methylphenyl, 3-chloro-2-methylphenyl, 3-chloro-4- methylphenyl, 4-chloro-2-methylphenyl, 4-chloro-3-methylphenyl, 5-chloro-2- methylphenyl, 2,3-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2,3- di methylphenyl, 3,4-dimethylphenyl, and the like.
The term "heteroaryl" means an aromatic ring containing one or more heteroatoms. The heteroaryl is optionally substituted with one or more groups enumerated for aryl. Examples of heteroaryl include, but are not limited to, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazoyl, pyrazinyl, oxazolyl, thiazolyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl, and quinazolinyl, and the like. The term "cycloalkenyl" means a cycloalkyl group having one or more carbon-carbon double. Example includes cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclobutadiene, cyclopentadiene, and the like.
The term "patient" means all mammals including humans. Examples of patients include humans, cows, dogs, cats, goats, sheep, pigs, and rabbits.
A "therapeutically effective amount" is an amount of a compound of the present invention that when administered to a patient ameliorates a symptom of dyslipidemia, non-insulin dependent diabetes mellitus, obesity, hyperglycemia, hypercholesteremia, hyperlipidemia, atherosclerosis, hypertriglyceridemia, or hyperinsulinemia.
The term "a pharmaceutically acceptable salt" refers to the relatively non- toxic, inorganic and organic base or acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free form with a suitable organic or inorganic base or acid and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts, and the like. These also include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. (See, for example, Berge S.M., et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977;66:1-19, which is incoφorated herein by reference.) The free base form may be regenerated by contacting the salt form with a base. While the free base may differ from the salt form in terms of physical properties, such as solubility, the salts are equivalent to their respective free bases for the puφoses of the present invention. The symbol " w sr » indicates a point of attachment.
The present invention provides compounds capable of modulating PPAR activity. Compounds of the present invention are described by Formula I:
Figure imgf000013_0001
or a pharmaceutically acceptable salt thereof, where:
W is O, S, CR5R6, -(CH2)p-cycloalkylene, or -(CH2)p-heterocycloalkylene; X° and X1 are independently O or S;
Ar1 is a unsubstituted or substituted aryl or heteroaryl;
R1, R2, R3, and R4 are independently hydrogen, lower alkyl, lower alkoxy, haloalkyl,-O-(CH2)pCF3, halogen, nitro, cyano, -OH, -SH, -CF3, -S(O)palkyl, S(O)paryl, -(CH2)mOR7, -(CH2)mNR8R9, -COR7, -CO2H, -CO2R7, or -NR8R9; R5 and R6 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl, or joined together to form a 3 to 7 member cycloalkyl or cycloalkenyl;
R7 is independently hydrogen, alkyl, alkenyl, alkynyl, or aryl;
R8 and R9are independently hydrogen, alkyl, alkenyl, alkynyl, -COalkyl, - COaryl, cycloalkyl, -CO2alkyl, -CO2aryl, -SO2alkyl, -SO2aryl, or joined together to form a 4 to 7 member ring having 1 to 3 heteroatoms;
R10 and R11 are independently hydrogen, halo, aryl, or hereroaryl; m is 0 to 5; n is 0 to 5; and p is 0 to 2; with the following provisos: that when W is O, n = 1 , and R1 is hydrogen, R2 and R4 are not hydrogen or R2 and R3 are not hydrogen; that when W is O, n - 1 , and R2 is hydrogen, R1 and R3 are not hydrogen or R1 and R4 are not hydrogen; that when W is O, n = 1 , and R3 is hydrogen, R1 and R4 are not hydrogen or R2 and R4 are not hydrogen; and that when W is O, n = 1 , and R4 is hydrogen, R1 and R3 are not hydrogen or
R and R are not hydrogen.
Examples of compounds of Formula I include those where W is O, Ar is substituted aryl, and n is i . For example compounds of Formula I where W is O, Ar1 is substituted aryl, and n is 1 include those where Ar1 is 4-trifluoromethylphenyl.
Other examples of compounds of Formula I include those where R1, R2, R3, and R4 are independently hydrogen, lower alkyl, lower alkoxy, -(CH2)mNR8R9, or - (CH2)mOR7 ; where R7 is alkyl, R8 and R9 are independently hydrogen, alkyl, or- COalkyl. For example such compounds include those compounds where R1, R2, R3, and R4 are the following combinations shown in Table 1 below, provided that R1, R' R3, and R4 are not each hydrogen when W is O.
Table 1
Figure imgf000015_0001
Other examples of compounds of Formula I also include those where R2 is hydrogen; R1, R3, and R4 are independently lower alkyl, lower alkoxy, haloalkyl,-O- (CH2)PCF3, halogen, nitro, cyano, -OH, -SH, -CF3, -S(O)palkyl, S(O)paryl, - (CH2)mOR7, -(CH2)mNR8R9, -COR7, -CO2H, -CO2R7, or -NR8R9; R7 is hydrogen, alkyl, alkenyl, alkynyl, or aryl; and R8 and R9 are independently hydrogen, alkyl, alkenyl, alkynyl, -COalkyl, -COaryl, cycloalkyl, -CO2alkyl, -CO2aryl, -SO2alkyl, - SO2aryl, or joined together to form a 4 to 7 member ring having 1 to 3 heteroatoms.
Additional examples of compounds of Formula I also include those where R2 and R are both hydrogen. For example compounds of Formula I where R and R are hydrogen include those where R2 and R3 are hydrogen, and R1 and R4 are lower alkyl, such as methyl, ethyl, isopropyl, n-propyl, t-butyl, n-butyl, and isobutyl, or lower alkoxy, such as methoxy, ethoxy, isopropoxy, n-propoxy, t-butoxy, n-butoxy, and isobutoxy. More specific examples of compounds of Formula I where R and R are hydrogen include those where R2 and R3 are hydrogen, R1 is lower alkyl, and R4 is lower alkoxy.
Other examples of compounds of Formula I include those where R1 and R1 ' are independently fluorine, phenyl or pyrrolyl;
Additional examples of compounds of Formula I include those where W is CR5R6, -(CH2)p-cycloalkylene, or -(CH2)p-heterocycloalkylene, R5 and R6 are joined together to form a 3 to 7 member cycloalkyl or cycloalkenyl ring, and p is 0 to 2. For example, compounds of Formula I where W is CR5R , -(CH2)p-cycloalkylene, or - (CH2)p-heterocycloalkylene include those where W is
Figure imgf000016_0001
or Other examples, compounds of Formula I where W is CR5R6, -(CH2)P- cycloalkylene, or -(CH2)p-heterocycloalkylene include those where X° and X1 are S.
Additional examples, compounds of Formula I where W is CR 5D R6 , -(CH2)| p cycloalkylene, or -(CH2)p-heterocycloalkylene include those where Ar j is 4- trifluoromethylphenyl.
Further examples, compounds of Formula I where W is CR5R , -(CH2)P- cycloalkylene, or -(CH2)p-heterocycloalkylene include those where R1, R2, R3, and R4 are independently hydrogen, lower alkyl, lower alkoxy, halogen, -CF3, -(CH2)mOR7, or -(CH2)mNR8R9; R7 is hydrogen, or alkyl; and R8 and R9are independently hydrogen, alkyl, or -COalkyl. Such compounds include those where R , R , R , and R4 are independently hydrogen, methyl, ethyl, isopropyl, n-propyl, t-butyl, n-butyl, or isobutyl, methoxy, ethoxy, isopropoxy, n-propoxy, t-butoxy, n-butoxy, isobutoxy, - (CH2)-OCH3, or -NH-COCH3.
Examples of compounds of Formula I include
{2,5-Dimethyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy}-acetic acid; {5-Ethyl-2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanylj-phenoxy} -acetic acid;
{5-Isopropyl-2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanylj-phenoxy} -acetic acid;
{2,6-Dimethyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy} -acetic acid;
{5-Methoxy-2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy} -acetic acid;
{2-Methoxy-5-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy} -acetic acid; {3,5-Dimethyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy}-acetic acid;
{3-Methoxy-5-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy}-acetic acid; {2-Isopropyl-5-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy}-acetic acid
{2,6-Diisopropyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy}-acetic acid;
2-Methyl-2-{4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenyl }-propionic acid;
2-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]- phenyl }-cyclopropanecarboxylic acid; l-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]- phenyl }-cyclopropanecarboxylic acid; l-{4-[4-Methyl-2-(4-trifluoromethyl -phenyl)-thiazol-5-ylmethylsulfanyl]- phenyl }-cyclopentanecarboxylic acid;
4-Methyl-4-{4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethy lsulfanylj-phenyl }-pentanoic acid;
3-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]- phenoxy}-propionic acid;
2-{3-Methoxy-4-[4-methyI-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanylj-phenyl }-2-methyl-propionic acid;
3-Methyl-3-{4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenyl }-butyric acid; 3-{2,4-Dimethoxy-5-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenyl }-propionic acid;
3-{2,5-Dimethoxy-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenyl }-propionic acid; {2,4-Dimethoxy-5-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl] }-acetic acid;
3-{4-[4-Methtyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-phenyl }-
2-pyrrol-l-yl-propionic acid; 3- { 4- [4-Methtyl-2-(4-trifluoromethyl-phen yl )-thi azol -5 -yl methoxy]-phenyl } -
2-phenyl-propionic acid;
3-{4-[4-Methtyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]- phenyl } -2-pyrrol- 1 -yl-propionic acid;
2-[5-(acetylamino)-2-methyl-4-({4-methyl-2-[4-(trifluoromethyl)phenyl](l ,3- thiazol-5-yl)}methylthio)phenoxy]acetic acid;
2-[5-fluoro-2-methy 4-({4-methyl-2-[4-(trifluoromethyl)phenyl](l,3-thiazol-
5-yl) }methylthio)phenoxy]acetic acid;
2-[5-methoxy-2-methyl-4-({4-methyl-2-[4-(trifluoromethyl)phenyl](l ,3- thiazol-5-yl)}methoxy)phenylthio]acetic acid; 2,2-difluoro-2-[5-methoxy-2-methyl-4-({4-methyl-2-[4-
(trifluoromethyl)phenyl](l,3-thiazol-5-yl)}methoxy)phenylthio]acetic acid; l-[{3-Methoxy-4-[4-methyl-2(4-trifluoromethylphenyl)thiazol-5- ylmethylsulfanyl]benzyl }pyrrolidine-2-carboxylic acid;
({2-Methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy}-phenyl-acetic acid;
{5-Chloro-2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanylj-phenoxy} -acetic acid;
2-[5-(methoxymethyl)-2-methyl-4-({4-methyl-2-[4-
(trifluoromethyl)phenyl](l,3-thiazol-5-yl)}methylthio)phenoxy]acetic acid; (4-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]- phenyl}cyclohexyl)-acetic acid; and pharmaceutically acceptable salts thereof.
Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R or S configuration. The present invention includes all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof. Stereoisomers may be obtained, if desired, by methods known in the art as, for example, the separation of stereoisomers by chiral chromatographic columns. Additionally, the compounds of the present invention may exist as geometric isomers. The present invention includes all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the appropriate mixtures thereof.
In some situations, compounds may exist as tautomers. All tautomers are included within Formula I and are provided by this invention.
In addition, the compounds of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the puφoses of the present invention.
The present invention includes all pharmaceutically acceptable, non-toxic esters of the compounds of Formula I. Such esters include Cι-C6 alkyl esters wherein the alkyl group is a straight or branched chain. Acceptable esters also include C5-C7 cycloalkyl esters as well as arylalkyl esters such as, but not limited to benzyl. Cι-C alkyl esters are preferred. Esters of the compounds of the present invention may be prepared according to conventional methods.
The compounds of the present invention are suitable to be administered to a patient for the treatment, control, or prevention of non-insulin dependent diabetes mellitus, hypercholesteremia, hyperlipidemia, obesity, hyperglycemia, hyperlipidemia, atherosclerosis, hypertriglyceridemia, and hyperinsulinemia. Accordingly, the compounds may be administered to a patient alone or as part of a composition that contains other components such as excipients, diluents, and carriers, all of which are well-known in the art. The compositions can be administered to humans and/or animals either orally, rectally, parenterally (intravenously, intramuscularly, or subcutaneously), intracisternally, intravaginally, intraperitoneally, intravesically, locally (powders, ointments, or drops), or as a buccal or nasal spray.
Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absoφtion of the injectable pharmaceutical form can be brought about by the use of agents delaying absoφtion, for example, aluminum monostearate and gelatin.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (c) humectants, as for example, glycerol; (d) disintegrating agents, as for example, agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solution retarders, as for example paraffin;
(f) absoφtion accelerators, as for example, quaternary ammonium compounds;
(g) wetting agents, as for example, cetyl alcohol and glycerol monostearate; (h) adsorbents, as for example, kaolin and bentonite; and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar, as well as high molecular weight polyethyleneglycols, and the like.
Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others well-known in the art. They may contain opacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions which can be used are polymeric substances and waxes. The active compounds can also be in micro- encapsulated form, if appropriate, with one or more of the above-mentioned excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1 ,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols and fatty acid esters of sorbitan or mixtures of these substances, and the like.
Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar- agar and tragacanth, or mixtures of these substances, and the like.
Compositions for rectal administrations are preferably suppositories which can be prepared by mixing the compounds of the present invention with suitable non- irritating excipients or carriers such as cocoa butter, polyethyleneglycol, or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.
Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays, and inhalants. The active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required. Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.
The compounds of the present invention can be administered to a patient at dosage levels in the range of about 0.1 to about 2,000 mg per day. For a normal human adult having a body weight of about 70 kilograms, a dosage in the range of about 0.01 to about 10 mg per kilogram of body weight per day is preferable. However, the specific dosage used can vary. For example, the dosage can depend on a numbers of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well-known to those skilled in the art.
PREPARATION OF COMPOUNDS OF THE INVENTION
The present invention contains compounds that can be synthesized in a number of ways familiar to one skilled in organic synthesis. The compounds disclosed herein can be synthesized according to the methods described below and in the examples, along with methods typically utilized by a synthetic chemist, and combinations or variations of those methods, which are generally known to one skilled in the art of synthetic chemistry. The synthetic route of compounds in the present invention is not limited to the methods outlined below. It is assumed one skilled in the art will be able to use the schemes outlined below to synthesize compounds claimed in this invention. Individual compounds may require manipulation of the conditions in order to accommodate various functional groups. A variety of protecting groups generally known to one skilled in the art may be required. Purification, if necessary, can be accomplished on a silica gel column eluted with the appropriate organic solvent system. Also, reverse phase HPLC or recrystallization may be employed.
The compounds or Formula I can be prepared by reacting:
Figure imgf000025_0001
in a solvent in the presence of a base such as cesium carbonate, with the aryl halide:
Figure imgf000025_0002
wherein:
W, Y, n, R1, R2, R3, R4, X°, X1 and Ar1 are the same as defined above for Formula I;
R12 is a lower alkyl; and X is a halogen.
The resulting ester is then converted to the compounds of Formula I by various methods known in the art for the conversion of esters to acids, such as via hydrolysis for example. Useful aryl halides include, for example, 5-chloromethyl-4- methyl-2-(4-trifluoromethyl-phenyl)-thiazole.
The compounds of Formula I can be prepared using the synthetic route outlined in Scheme 1 when W is O or S and X° is S. With reference to Scheme 1 , compounds of the general formula A are thiocyanated with a mixture of bromine and sodium thiocyanate to give compounds of the general formula B. Compounds of the general formula B are then alkylated with the haloester C to give compounds of the general formula D. A useful haloester C is the corresponding bromoester. Compounds of the general formula E are then prepared by reduction of D with dithiothreitol in methanol. Compounds of the general formula E are then alkylated with the halide compound IB to form compound F. Suitable halide compounds IB include, for example, 5-chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole. Compounds of the general formula F are then saponified with LiOH in THF to give the final compound G. W, Y, R1, R2, R3, and R4 are the same as defined above for Formula I above; X is a halogen. Compound G corresponds to compounds described by Formula I above when X° is S.
Scheme 1
Figure imgf000027_0001
alkylation
B
Figure imgf000027_0002
Figure imgf000027_0003
Alternatively, compounds of Formula I can be prepared using the synthetic route outlined in Scheme 2 when X° is S. With reference to Scheme 2, compounds of the general formula H are debenzylated and then reacted with 2-chloro-N,N- dimethyl-thioacetamide to form compound J. A useful method for stepl is reaction with hydrogen gas in the presence of carbon activated palladium. Compound J is then heated followed by saponification to form compound E. Compounds of the general formula E are then alkylated with the halide compound IB to form compound F. Suitable halide compounds IB include, for example, 5-chloromethyl-4-methyl-2- (4-trifluoromethyl-phenyl)-thiazole. Compounds of the general formula F are then saponified with LiOH in the THF to give the final compound G. W, Y, R1, R2, R3, and R4 are the same as defined above for Formula I above; X is a halogen. Compound G corresponds to compounds described by Formula I above when X° is S.
Scheme 2
Figure imgf000028_0001
1. Tetradecane, heat
2. NaOMe, MeOH
Figure imgf000028_0002
E
Figure imgf000028_0003
Finally, compounds of Formula I can be prepared using the synthetic route outlined in Scheme 3. With reference to Scheme 3, compounds of the general formula K are converted to the ester L. A useful method includes reacting compound K with an alcohol in the presence of an acid such as hydrochloric acid, although any compatible method for esterification may be used. Ester L is then reacted with cholorsulfonic acid to form compound M. Compound M is then reduced to form compound E. Compounds of the general formula E are then alkylated with the halide compound IB to form compound F. Suitable halide compounds IB include, for example, 5-chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole. Compounds of the general formula F are then saponified with LiOH in the THF to give the final compound G. W, Y, R1, R2, R3, and R4 are the same as defined above for Formula I above; X is a halogen. Compound G corresponds to compounds described by Formula I above when X° is S.
Scheme 3
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000030_0002
The following non-limiting descriptions also demonstrate methods for the synthesis of compounds of Formula I.
Example 1 Synthesis of |2.5-Dimethyl-4-r4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyll-phenoxyl-acetic acid (Compound 1)
Figure imgf000030_0003
Preparation of [4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-vn-methanol (compound 1A)
Figure imgf000031_0001
1A
A solution of 4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole-5-carboxylic acid ethyl ester (3.0 g, 9.5 mmol) in 25 mL THF at 0 °C was treated portionwise with lithium aluminum hydride (0.4 g, 10.5 mmol). After 4 hours, the reaction mixture was carefully quenched with water, followed by the addition of 10 mL 6N NaOH. The reaction mixture was then extracted with EtOAc, dried, and concentrated in vacuo. Recrystalisation from CHCl3/hexanes gave the title compound (2.2 g, 85%). 400 MHz Η NMR (DMSO- ) 68.03 (d, 2H, I = 8.3 Hz), 7.78 (d, 2H, J = 8.3 Hz), 5.66 (s(br), 1H), 4.62 (s, 2H), 2.31 (s, 3H).
Preparation of 5-Chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole (compound IB)
Figure imgf000031_0002
IB
Methanesulfonyl chloride (1.0 mL, 12.9 mmol) was added to a stirred solution of [4- methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-methanol (2.2 g, 8.1 mmol) and triethylamine (2.2 mL, 16.1 mmol) in 25 mL THF at 0 °C. After 3 hours, the reaction mixture was diluted with dichloromethane, washed with 1 x sat. NaHCO3, 1 x brine, dried (Na2SO4) and the solvent removed in vacuo to give 2.0 g (84%) of the title compound pure enough for subsequent use. 400 MHz Η NMR (DMSO-d6) δ 8.06 (d, 2H, J = 8.3 Hz), 7.80 (d, 2H, J = 8.3 Hz), 5.08 (s, 2H), 2.40 (s, 3H).
Preparation of 2,5-Dimethyl-4-thiocyanato-phenol (compound IC)
Figure imgf000032_0001
IC
The title compound was prepared in a manner analogous to compound 3A. 400 MHz Η NMR (DMSO- ) δ 10.0 (s, IH), 7.35 (s, IH), 6.73 (s, IH), 2.3 (s, 3H), 2.04 (s, 3H); MS m/z 180 (m+1).
Preparation of (2,5-Dimethyl-4-thiocyanato-phenoxy)-acetic acid methyl ester
(compound ID)
Figure imgf000032_0002
ID The title compound was prepared from compound IC in a manner analogous to compound 3B. 400 MHz Η NMR (DMSO- ) δ 7.07 (s, IH), 6.50 (s, IH), 4.56 (s, 2H), 3.76 (s, 3H), (s, IH), 2.26 (s, 3H), 2.17 (s, 3H); MS m/z 252 (m+1 ).
Preparation of (4-Mercapto-2,5-dimethyl-phenoxy)-acetic acid methyl ester (compound IE)
Figure imgf000032_0003
IE The title compound was prepared from compound 1 D in a manner analogous to compound 3C. 400 MHz Η NMR (DMSO- ) δ 7.07 (s, IH), 6.50 (s, IH), 4.56 (s, 2H), 3.76 (s, 3H), 3.07 (s, IH), 2.26 (s, 3H), 2.17 (s, 3H); MS m/z 227 (M+1).
Preparation of {2,5-Dimethyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol- 5-ylmethylsulfanyl]-phenoxy}-acetic acid methyl ester (compound IF)
Figure imgf000033_0001
IF
Compound IE (207 mg, 0.92 mmol) was dissolved in 5 ml anhydrous acetonitrile. Compound IB (294 mg, 1 mmol) was added followed by cesium carbonate ( 600 mg, 1.84 mmol). The reaction was stirred at ambient temperature for 2 hours, filtered and concentrated. Purification by flash column chromatography afforded the title compound. 400 MHz Η NMR (DMSO- ) δ 8.00 (d, 2H, J = 8 Hz), 7.76 (d, 2H, J = 8.4 Hz), 7.15 (s, IH), 6.72 (s, IH), 4.76 (s, 2H), 4.22 (s, 2H), 2.17 (s, 3H), 3.63 (s, 3H), 2.17 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H). MS m/z 482 (M+1).
Preparation of {2,5-Dimethyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiaζol-
5-ylmethylsuIfanyl]-phenoxy}-acetic acid (Compound 1)
Compound IF (360 mg, 0.75 mmol), dissolved in 5 ml THF and 1 ml water, was treated with lithium hydroxide monohydrate (95 mg, 2.25 mmol); stirring at room temperature for 1 hour. The reaction mixture was then acidified to about pH 3 with 2
N HC1. The reaction was then extracted into ethyl acetate (2x20 ml). The organic extracts were washed with brine, dried over anhydrous sodium sulfate, decanted, and concentrated. The title compound was then recrystalized from chloroform/ hexanes. Mp 173-176 °C; IR (thin film) cm"1: 2928, 1732, 1328, 1 1 13; 400 MHz Η NMR (DMSO- ) δ 12.97 (s(br), IH), 8.00 (d, 2H, J = 8 Hz), 7.76 (d, 2H, J = 8.4 Hz), 7.15 (s, IH), 6.69 (s, IH), 4.63 (s, 2H), 4.22 (s, 2H), 2.17 (s, 3H), 2.09 (s, 3H), 6.00 (s, 2H), 2.04 (s, 3H); MS m/z 468 (M+1). Anal. Calc'd for C22H20F3NO3S2 C, 56.52; H, 4.31 ; N, 3.00; found: C, 56.55; H, 4.31; N, 2.94.
Example 2
Synthesis of {5-Ethyl-2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiaζol- 5-ylmethylsulfanyl1-phenoxyl-acetic acid (Compound 2)
Figure imgf000034_0001
Preparation of 5-Ethyl-2-methyl-phenol (compound 2A)
Figure imgf000034_0002
2A
A 3:1 mixture of 1 -(5-ethyl-2-methyl-phenyl)-ethanone and 1 -(2-ethyl-5-methyl- phenyl)-ethanone (J. Chem. Soc, 152, 1 123) (3.6 g, 22 mmol), m-chloroperbenzoic acid (8.4 g, 29 mmol), and p-toluenesulfonic acid (0.5 g, 2.6 mmol) in 100 mL dichloromethane was heated at reflux for 20 hours. The reaction was then cooled and washed with KI(aq.) (2 x 75 mL), NaHSO3 (2 x 75mL), dried (Na2SO4) and concentrated in vacuo. The resulting residue was taken up in Et2O and washed with sat. NaHCO3(l x 75 mL), dried (Na2SO ) and concentrated in vacuo to give 3.2 g of the crude product pure enough for subsequent use. 400 MHz Η NMR (DMSO- 6) δ 7.1 1 (d, 2H, J = 7.8 Hz), 6.96 (d, 2 H, J = 7.8 Hz), 6.83 (s, IH), 6.80 (s, IH), 2.51 (q, 2H, J = 7.6 Hz), 2.37 (q, 2H, J = 7.6 Hz), 2.23 (s, 6H), 2.01 (s, 6H), 1.10 (t, 3H, J = 7.6 Hz), 1.08 (t, 3H, J = 7.6 Hz). The crude product was then dissolved in MeOH (75 mL) and K2CO3 (2.5 g, 18 mmol) was added followed by stirring for 15 minutes. The reaction mixture was then filtered, the filtrate collected and concentrated in vacuo. The residue was taken up in Et2O and washed with 2 M HCL (1 x 50 mL), brine (1 x 50 mL), dried (Na2SO ) and the solvent removed in vacuo to give the title compound and its regioisomer as a 3:1 mixture pure enough for subsequent use. 400 MHz Η NMR (DMSO- ) δ 400 MHz Η NMR (DMSO-d6) δ 6.87 (d, IH, J = 7.3 Hz (title compound)), 6.85 (d, IH, J = 7.3 Hz), 6.54 (s, 1 W(title compound)), 6.46 (d, 2H, J = 7.3 Hz), 2.44 ( , 4H), 2.37, 2.00 (s, 6H), 1.06 (m, 6H).
Preparation of 5-Ethyl-2-methyl-4-thiocyanato-phenol (compound 2B)
Figure imgf000035_0001
2B
2B was prepared from 2A in a similar manner as described for compound 3A to give, after purification by flash column chromatography (gradient elution: 100% hexanes to 20% EtOAc/hexane) and then recrytalisation from CHCl3/hexanes, 0.8 g (29%) of the title compound as a single regioisomer. 400 MHz Η NMR (DMSO-d6) δ 7.36 (s, 1H), 6.77 (s, IH), 2.67 (q, 2H, J = 7.4 Hz), 2.05 (s, 3H), 1.13 (t, 3H, J = 7.4 Hz); MS m/z 194 (M+1).
Preparation of (5-Ethyl-2-methyl-4-thiocyanato-phenoxy)-acetic acid methyl ester (compound 2C)
Figure imgf000036_0001
2C
2C was prepared from 2B in a similar manner as described for compound 3B to give 1.1 g (95%) of the title compound pure enough for subsequent use. 400 MHz 1H NMR (DMSO- ) δ 7.46 (s, IH), 6.90 (s, IH), 4.87 (s, 2H), 3.65 (s, 3H), 2.72 (q, 2H, I = 7.5 Hz), 2.13 (s, 3H), 1.14 (t, 3H, J = 7.5 Hz).
Preparation of (5-Ethyl-4-mercapto-2-methyl-phenoxy)-acetic acid methyl ester (compound 2D)
Figure imgf000036_0002
2D
2D was prepared from 2C in a similar manner as described for compound 3C to give, after purification by flash column chromatography (gradient elution: 100% hexanes to 30% EtOAc/hexanes), 0.3 g (32%) of the title compound. 400 MHz Η NMR (DMSO-dβ) δ 7.09 (s, IH), 6.72 (s, IH), 4.81 (s, 2H), 3.64 (s, 3H), 2.55 (q, 2H, J = 7.5 Hz), 2.05 (s, 3H), 0.99 (t, 3H, J = 7.5 Hz); MS m/z 241 (M+1). Preparation of {5-Ethyl-2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)- thiazol-5-ylmethylsulfanyl]-phenoxy}-acetic acid methyl ester (compound 2E)
Figure imgf000037_0001
2E
Compound 2D and 5-chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole were coupled in a similar manner as described for compound IF to provide, after purification by flash column chromatography (gradient elution: 100% hexanes to 30% EtOAc/hexanes), the title compound (0.24 g , 59%) as a yellow solid. IR (thin film) cm"1: 1749, 1326; 400 MHz Η NMR (DMSO- ) δ 7.98 (d, 2H, I = 8.0 Hz), 7.76 (d, 2H, J = 8.0 Hz), 7.19 (s, 1 H), 6.68 (s, 1 H), 4.77 (s, 2H), 4.24 (s, 2H), 3.63 (s, 3H), 2.54 (q, 2H, J = 7.6 Hz), 2.09 (s, 3H), 2.06 (s, 3H), 0.97 (t, 3H, J = 7.6 Hz); MS m/z 496 (M+1); Anal. Calc'd for C24H24F3N,O3S2 C, 58.17; H, 4.88; N, 2.83; found: C, 58.19; H, 4.80; N, 2.76.
Preparation of {5-Ethyl-2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)- thiaζol-5-ylmethylsulfanyl]-phenoxy}-acetic acid (Compound 2)
Compound 2E was saponified in the same manner as described for compound 1 to give, after recrystalisation from CHCl3/hexanes, the title compound (0.12 g, 96%) as a pale yellow solid, mp 169-171 °C; IR (thin film) cm"1: 1736, 1325; 400 MHz Η NMR (DMSO- ) δ 7.98 (d, 2H, J = 8.0 Hz), 7.76 (d, 2H, I = 8.0 Hz), 7.17 (s, IH), 6.66 (s, IH), 4.65 (s, 2H), 4.23 (s, 2H), 2.54 (q, 2H, J = 7.6 Hz), 2.09 (s, 3H), 2.05 (s, 3H), 0.97 (t, 3H, I = 7.6 Hz); MS m/z 482 (M+1); Anal. Calc'd for C24H24F3N,O3S2 0.5 H2O C, 56.31 ; H, 4.73; N, 2.86; found: C, 56.53; H, 4.69; N, 2.68. Example 3
Synthesis of 15-Isopropyl-2-methyl-4- r4-methyl-2-(4-trifluoromethyl-phenyl)- thiazol-5-ylmethylsulfanyll-phenoxy)-acetic acid (Compound 3)
Figure imgf000038_0001
Preparation of 5-Isopropyl-2-methyl-4-thiocyanato-phenol (compound 3A)
Figure imgf000038_0002
3A
A rapidly stirred solution of 5-isopropyl-2-methyl-phenol (10 g, 67 mmol), sodium thiocyanate (15.6 g, 214 mmol), and sodium bromide (6.8 g, 66 mmol) in 40 mL MeOH at 0 °C was treated with bromine in 40 mL MeOH by dropwise addition over 30 minutes. After completion of the bromine addition, the reaction mixture was heated at 50 °C for 45 minutes. The reaction mixture was then cooled and concentrated in vacuo to about 20 mL. The resulting residue was taken up in EtOAc and filtered. The filtrate was collected and washed with saturated Na2CO3 (1 x 50 mL), brine (1 x 50 mL) dried (Na2SO ), and the solvent removed in vacuo. Purification by flash column chromatography (gradient elution: 5% EtOAc/hexanes to 35% EtOAc/hexanes to 55% EtOAc/hexanes) gave the title compound (7.9 g, 57 %) as a yellow solid, mp 72-75 °C; 400 MHz Η NMR (DMSO-d6) δ 10.0 (s, IH), 7.37 (s, IH), 6.81 (s, IH), 3.31 (m, IH), 2.04 (s, 3H), 1.14 (d, 6H, J = 6.8 Hz); MS m/z 208 (M+1).
Preparation of (5-Isopropyl-2-methyl-4-thiocyanato-phenoxy)-acetic acid methyl ester (compound 3B)
Figure imgf000039_0001
A solution of 5-isopropyl-2-methyl-4-thiocyanato-phenol (3.0 g, 14 mmol), methyl bromoacetate (0.90 g, 15.4 mmol), and cesium carbonate (6.8 g, 21 mmol) in 50 mL acetonitrile was heated at 60 °C for 3 hours. PS-Trisamine scavenger resin was then added to the warmed solution followed by an additional 30 minutes heating. The reaction mixture was then cooled and filtered. The filtrate was collected, diluted with 100 mL ether, washed with brine (1 x 50 mL), dried (Na2SO ), and the solvent removed in vacuo to give 3.8 g (94%) of the title compound as an orange solid, pure enough for subsequent use. mp 67-69 °C; 400 MHz Η NMR (DMSO- 6) δ 7.46 (s, lH), 6.88 (s, 1H), 4.91 (s, 2H), 3.65 (s, 3H), 3.31 (m, IH), 2.13 (s, 3H), 1.16 (d, 6H, 7 = 6.8 Hz); MS m/z 279 (M+).
Preparation of (5-Isopropyl-4-mercapto-2-methyl-phenoxy)-acetic acid methyl ester (compound 3C)
Figure imgf000039_0002
3C A solution of (5-isopropyl-2-methyl-4-thiocyanato-phenoxy)-acetic acid methyl ester (3g, 10.7 mmol), dithiothreitol (2.1 g, 13.9 mmol), and KH2PO4 (5 mL of a .02M solution) in 40 mL MeOH was heated at reflux for 1 hour after which time thin-layer chromatography (33% EtOAc hexanes) indicated the reaction to be complete. The reaction was cooled and concentrated in vacuo to about 10 mL. The resulting residue was diluted with 100 mL ether and washed with brine (2 x 50 mL), dried (Na2SO ), and the solvent removed in vacuo. Purification by flash column chromatography (gradient elution: 5% EtOAc/hexanes to 25% EtOAc/hexanes to 55% EtOAc/hexanes) gave the title compound (2.0 g, 72 %) as a yellow oil. 400 MHz Η NMR (DMSO- 6) δ 7.10 (s, IH), 6.64 (s, IH), 4.75 (s, 2H), 3.63 (s, 3H), 3.02 (septet, IH, J = 6.8 Hz), 2.05 (s, 3H), 1.08 (d, 6H, J = 6.8 Hz); MS m/z 255 (M+1 ).
Preparation of {5-IsopropyI-2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyI)- thiazol-5-ylmethylsulfanyl]-phenoxy}-acetic acid methyl ester (compound 3D)
Figure imgf000040_0001
3D
3C and 5-chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole (compound IB) were coupled in a similar manner as described for compound IF to provide, after purification by flash column chromatography (gradient elution: 10% EtOAc/hexanes to 35% EtOAc/hexanes), the title compound (0.66 g , 82%) as a yellow solid. IR (thin film) cm"1: 2960, 1763, 1324; 400 MHz Η NMR (DMSO-rf6) δ 7.97 (d, 2H, J = 8.1 Hz), 7.76 (d, 2H, J = 8.1 Hz), 7.23 (s, IH), 6.64 (s, IH), 4.80 (s, 2H), 4.21 (s, 2H), 3.61 (s, 3H), 3.31 (m, IH), 2.06 (s, 3H), 2.03 (s, 3H), 1.08 (d, 6H, J = 6.8 Hz); MS m/z 510 (M+1); Anal. Calc'd for C25H26F3N,O3S2 C, 58.92; H, 5.14; N, 2.75; found: C, 58.50; H, 5.39; N, 2.66. Preparation of {5-Isopropyl-2-methyl-4-[4-methyl-2-(4-trifluoromethyI-phenyl)- thiazol-5-ylmethylsulfanyl]-phenoxy}-acetic acid (Compound 3)
3D was saponified in the same manner as described for compound 1 to give, after recrystalisation from CHCl3/hexanes, the title compound (0.24 g, 71 %) as a white solid, mp 132-134 °C; IR (thin film) cm"1: 1744, 1325; 400 MHz ]H NMR (DMSO- d6) δ 7.97 (d, 2H, J = 8.3 Hz), 7.76 (d, 2H, J = 8.3 Hz), 7.22 (s, IH), 6.64 (s, IH), 4.67 (s, 2H), 4.20 (s, 2H), 3.31 (m, IH), 2.06 (s, 3H), 2.03 (s, 3H), 0.93 (d, 6H, J = 6.8 Hz); MS m/z 496 (M+1); Anal. Calc'd for C24H24F3NιO3S2 0.1 H2O C, 57.96; H, 4.90; N, 2.82; found: C, 57.62; H, 4.82; N, 2.68.
Example 4
Synthesis of {2.6-Dimethyl-4-r4-methyl-2-(4-trifluoromethyl-phenyl)-thiaζol-5- ylmethylsulfanyll-phenoxyl-acetic acid (Compound 4)
Figure imgf000041_0001
4
Preparation of 2,6-Dimethyl-4-thiocyanato-phenol (compound 4A)
Figure imgf000041_0002
Compound 4A was prepared from 2,6-dimethylphenol in a similar manner as described for compound 3A. 400 MHz 1H NMR (DMSO-40 δ 8.96 (s, IH), 7.22 (s, 2H), 2.13 (s, 6H).
Preparation of (2,6-Dimethyl-4-thiocyanato-phenoxy)-acetic acid methyl ester (compound 4B)
Figure imgf000042_0001
4B
Compound 4B was prepared from compound 4A in a similar manner as described for compound 3B to give 2.5 g (46%) of the title compound pure enough for subsequent use. 400 MHz Η NMR (DMSO- 6) δ 7.1 1 (s, 2H), 4.41 (s, 2H), 3.63 (s, 3H), 2.14 (s, 6H).
Preparation of (4-Mercapto-2,6-dimethyl-phenoxy)-acetic acid methyl ester (compound 4C)
Figure imgf000042_0002
4C
Compound 4C was prepared from compound 4B in a similar manner as described for compound 3C to give, after purification by flash column chromatography (gradient elution: 100% hexanes to 30% EtOAc/hexanes), 1.8 g (82%) of the title compound. 400 MHz Η NMR (DMSO- ) δ 6.90 (s, 2H), 5.51 (s, IH), 4.39 (s, 2H), 3.66 (s, 3H), 2.10 (s, 6H); MS /z 225 (M-l). Preparation of {2,6-Dimethyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol- 5-ylmethylsulfanyl]-phenoxy}-acetic acid methyl ester (compound 4D)
Figure imgf000043_0001
4D
Compound 4C and 5-chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole were coupled in a similar manner as described for compound IF to provide, after purification by flash column chromatography (gradient elution: 10% EtOAc/hexanes to 35% EtOAc/hexanes), the title compound (0.61 g , 57%) as a yellow solid, mp 104-105 °C;IR (thin film) cm"1: 1754, 1325; 400 MHz Η NMR (DMSO-J6) δ 7.99 (d, 2H, J = 8.3 Hz), 7.76 (d, 2H, J = 8.3 Hz), 7.02 (s, 2H), 4.41 (s, 2H), 4.37 (s, 2H), 3.65 (s, 3H), 2.23 (s, 3H), 2.10 (s, 6H); MS m/z 482 (M+1 ); Anal. Calc'd for C23H22F3N,O3S2 C, 57.37; H, 4.60; N, 2.91 ; found: C, 57.43; H, 4.55; N, 2.94.
Preparation of {2,6-Dimethyl-4-[4-methyl-2-(4-trifluoromethyl-phenyI)-thiaζol- 5-ylmethylsulfanyl]-phenoxy}-acetic acid (Compound 4)
Compound 4D was saponified in the same manner as described for compound 1 to give, after recrystalisation from CHCl3/hexanes, the title compound (0.29 g, 86%) as a pale yellow solid, mp 157-158 °C; IR (thin film) cm"1: 1738, 1326; 400 MHz Η NMR (DMSO- ) δ 7.99 (d, 2H, J = 8.3 Hz), 7.76 (d, 2H, I = 8.3 Hz), 7.02 (s, 2H), 4.36 (s, 2H), 4.29 (s, 2H), 2.22 (s, 3H), 2.12 (s, 6H); MS m/z 468 (M+1); Anal. Calc'd for C22H20F3N,O3S2 0.2 H2O C, 56.09; H, 4.36; N, 2.97; found: C, 55.79; H, 4.22; N, 2.94. Example 5
Synthesis of {5-Methoxy-2-methyl-4-r4-methyl-2-(4-trifluoromethyl-phenyl)- thiazol-5-ylmethylsulfanyll-phenoxy|-acetic acid (Compound 5)
Figure imgf000044_0001
Preparation of 5-Methoxy-2-methyl-phenol (compound 5A)
Figure imgf000044_0002
2-Hydroxy-4-methoxy-benzaldehyde (3 g, 19.7 mmol), ammonium formate (6.2 g, 99 mmol) and palladium/carbon (900 mg @ 10%) were added to 26 ml glacial acetic acid and heated at 1 10 °C for 1 h. The reaction was cooled, filtered, and diluted with water (100 ml). The crude product was extracted with chloroform (3x50 ml), washed with water, brine, and dried over anhydrous sodium sulfate. The resulting solution was concentrated and used for the next step without further purification. MS m/z 139 (M+1). Preparation of 5-Methoxy-2-methyl-4-thiocyanato-phenol (compound 5B)
Figure imgf000045_0001
5B
Compound 5B was prepared from compound 5A in a manner analogous for example 3A. 400 MHz Η NMR (DMSO- ) δ 10.13 (s, IH), 7.25 (s, IH), 6.54 (s, IH), 3.77 (s, 3H), 2.0 (s, 3H). MS m/z 196 (M+1).
Preparation of (5-Methoxy-2-methyl-4-thiocyanato-phenoxy)-acetic acid methyl ester (compound 5C)
Figure imgf000045_0002
5C Compound 5C was prepared from compound 5B in a manner analogous to compound 3B. 400 MHZ Η NMR (DMSO- ) δ 7.33 (s, IH), 6.72 (s, IH), 4.93 (s, 2H), 3.84 (s, 3H), 3.66 (s, 3H), 2.09 (s, 3H); MS m/z 268 (M+1).
Preparation of (5-Methoxy-2-methyl-4-thiocyanato-phenoxy)-acetic acid methyl ester (compound 5D)
Figure imgf000045_0003
5D Compound 5D was prepared from compound 5C in a manner analogous to compound 3C. 400 MHz Η NMR (DMSO- 6) δ 7.02 (s, IH), 6.54 (s, IH), 4.79 (s, 2H), 4.41 (s, IH), 3.72 (s, 3H), 3.64 (s, 3H), 2.02 (s, 3H); MS m/z 243 (M+1).
Preparation of (5-Methoxy-2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)- thiaζol-5-ylmethylsulfanyl]-phenoxy}-acetic acid methyl ester (compound 5E)
Figure imgf000046_0001
Compound 5E was prepared from compound 5D in a manner analogous to compound 3D. 400 MHz Η NMR (DMSO-d6) δ 7.98 (d, 2H, J = 8.4 Hz), 7.76 (d, 2H, J = 8.4 Hz), 7.02 (s, IH), 6.54 (s, IH), 4.84 (s, 2H), 4.20 (s, 2H), 3.72 (s, 3H), 3.64 (s, 3H), 2.16 (s, 3H), 1.98 (s, 3H). Η NMR (DMSO- 6) δ MS m/z 498 (M+1).
Preparation of {5-Methoxy-2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)- thiaζol-5-ylmethy!sulfanyl]-phenoxy}-acetic acid (Compound 5)
Compound 5 was prepared from compound 5E in a manner analogous to compound 1. mp 21 1-213 °C; IR (thin film) cm"1: 2936, 1719, 1328, 1 1 1 1 ; 400 MHz Η NMR (DMSO-d6) δ 12.96 (s(br)), IH), 7.98 (d, 2H, J = 8.4 Hz), 7.76 (d, 2H, J = 8.4 Hz), 7.02 (d, IH, J = 0.4 Hz), 6.53 (s, IH), 4.71 (s, 2H), 4.20 (s, 2H), 3.73 (s, 3H), 2.16 (s, 3H), 1.98 (s, 3H); MS m/z 484 (M+1). Anal. Calc'd for C22H20F3NO4S2 C, 54.65; H, 4.17; N, 2.90; found: C, 54.68; H, 4.15; N, 2.84. Example 6
Synthesis of {2-Methoxy-5-methyl-4-r4-methyl-2-(4-trifluoromethyl-phenyl)- thiazol-5-ylmethylsulfanyll-phenoxyl-acetic acid (Compound 6)
Figure imgf000047_0001
Preparation of 2-Methoxy-5-methyl-phenol (compound 6A)
Figure imgf000047_0002
6A
The title compound was prepared from 3-hydroxy-4-methoxy-benzaldehyde in a manner analogous to compound 5A. 400 MHz Η NMR (DMSO-d6) δ 8.73 (s, IH), 6.71 (d, IH, 7 = 8.1 Hz), 6.53 (s, lH), 6.48 (d, IH, 7 = 8.1 Hz), 3.65 (s, 3H), 2.10 (s, 3H); MS m/z 139 (M+1).
Preparation of 2-Methoxy-5-methyl-4-thiocyanato-phenoI (compound 6B)
Figure imgf000047_0003
6B The title compound was prepared from compound 6A in a manner analogous to compound 3A. 400 MHz 1H NMR (DMSO-d6) δ 9.7 (s(br), IH), 7.15 (s, IH), 6.78 (IH), 3.73 (s, 3H), 2.3 (s, 3H); MS m/z 196 (M+1 ).
Preparation of (2-Methoxy-5-methyI-4-thiocyanato-phenoxy)-acetic acid methyl ester (compound 6C)
Figure imgf000048_0001
6C
The title compound was prepared from compound 6B in a manner analogous to compound 3B. 400 MHz Η NMR (DMSO-< 6) δ 7.22 (IH), 6.97 (s, IH), 4.81 (s, 2H), 3.75 (s, 3H), 3.65 (s, 3H), 2.34 (s, 3H); MS m/z 268 (M+1).
Preparation of (4-Mercapto-2-methoxy-5-methyl-phenoxy)-acetic acid methyl ester (compound 6D)
Figure imgf000048_0002
6D
The title compound was prepared from compound 6C in a manner analogous to compound 3C. 400 MHz Η NMR (DMSO- ) δ 6.96 (s, IH), 6.71 (s, IH), 4.88 (s, IH), 4.65 (s, 2H), 3.67 (s, 3H), 3.63 (s, 3H), 2.08 (s, 3H); MS m/z 243 (M+1). Preparation of {2-Methoxy-5-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)- thiazol-5-ylmethylsulfanyl]-phenoxy}-acetic acid methyl ester (compound 6E)
Figure imgf000049_0001
The title compound was prepared from compound 6D in a manner analogous to compound IF. 400 MHz Η NMR (DMSO- 6) δ 7.99 (d, 2H, J = 8.4 Hz), 7.76 (d, 2H, J = 8.4 Hz), 6.86 (s, IH), 6.75 (s, IH), 4.70 (s, 2H), 4.27 (s, 2H), 3.63 (s, 3H), 3.60 (s, 3H), 2.15 (s, 3H), 2.06 (s, 3H); MS m/z 498 (M+1).
Preparation of {2-Methoxy-5-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)- thiaζol-5-ylmethylsulfanyl]-phenoxy}-acetic acid (Compound 6)
The title compound was prepared from compound 6E in a manner analogous to compound 1. mp 165-167 °C; IR (thin film) cm"1: 2904, 1747, 1504, 1326; 400 MHz Η NMR (DMSO- ) δ 12.91 (s(br), IH), 7.99 (d, 2H, J = 8.4 Hz), 7.76 (d, 2H, J = 8.4 Hz), 6.85 (s, IH), 6.72 (s, IH), 4.59 (s, 2H), 4.27 (s, 2H), 3.60 (s, 3H), 2.15 (s, 3H), 2.06 (s, 3H); MS m/z 484 (M+1). Anal. Calc'd for C22H20F3NO4S2 C, 54.65; H, 4.17; N, 2.90; found: C, 54.21 ; H, 4.03; N, 2.79.
Example 7
Preparation of {3,5-Dimethyl-4-r4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol- 5-ylmethylsulfanyll-phenoxyl-acetic acid (Compound 7)
Figure imgf000050_0001
Preparation of 3,5-Dimethyl-4-thiocyanato-phenol (compound 7A)
Figure imgf000050_0002
7A
7A was prepared from 3,5-dimethylphenol in a similar manner as described for compound 3A. 400 MHz Η NMR (DMSO-d6) δ 9.61 (s, IH), 6.64 (s, 2H), 2.04 (s, 6H).
Preparation of (3,5-Dimethyl-4-thiocyanato-phenoxy)-acetic acid methyl ester (compound 7B)
Figure imgf000050_0003
7B Compound 7B was prepared from compound 7A in a similar manner as described for compound 3B to give 2.0 g (95%) of the title compound pure enough for subsequent use. 400 MHz 1H NMR (DMSO- 6) δ 6.63 (s, 2H), 4.72 (s, 2H), 3.62 (s, 3H), 2.08 (s, 6H).
Preparation of (4-Mercapto-3,5-dimethyl-phenoxy)-acetic acid methyl ester (compound 7C)
Figure imgf000051_0001
Compound 7C was prepared from compound 7B in a similar manner as described for compound 3C to give, after purification by flash column chromatography (gradient elution: 100% hexanes to 30% EtOAc/hexanes), 0.38 g (21 %) of the title compound. 400 MHz Η NMR (DMSO-d6) δ 6.66 (s, 2H), 4.68 (s, 2H), 4.20 (s, IH), 3.63 (s, 3H), 2.23 (s, 6H).
Preparation of {3,5-Dimethyl-4-[4-methyl-2-(4-trifluoromethyl-phenyI)-thiazol- 5-ylmethylsulfanyl]-phenoxy}-acetic acid methyl ester (compound 7D)
Figure imgf000051_0002
7D
Compound 7C and 5-chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole were coupled in a similar manner as described for compound IF to provide, after purification by flash column chromatography (gradient elution: 10% EtOAc/hexanes to 35% EtOAc/hexanes), the title compound (0.62 g , 79%) as a yellow solid, mp 113 °C; IR (thin film) cm"1: 1739, 1325; 400 MHz 1H NMR (DMSO-d6) δ 7.99 (d, 2H, 7 = 8.3 Hz), 7.76 (d, 2H, 7 = 8.3 Hz), 6.69 (s, 2H), 4.73 (s, 2H), 4.04 (s, 2H), 3.63 (s, 3H), 2.25 (s, 3H), 1.94 (s, 3H); MS m/z 482 (M+1 ); Anal. Calc'd for C23H22F3NιO3S2 C, 57.37; H, 4.60; N, 2.91 ; found: C, 57.22; H, 4.55; N, 2.78.
Preparation of {3,5-Dimethyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiaζol- 5-ylmethylsulfanyl]-phenoxy}-acetic acid (Compound 7)
Compound 7D was saponified in the same manner as described for compound IF to give, after recrystalisation from CHCl3/hexanes, the title compound (0.22 g, 76%) as a pale yellow solid, mp 184-185 °C; IR (thin film) cm"1: 1746, 1320; 400 MHz Η NMR (DMSO-dβ) δ 7.99 (d, 2H, 7 = 8.3 Hz), 7.76 (d, 2H, 7 = 8.3 Hz), 6.67 (s, 2H), 4.61 (s, 2H), 4.04 (s, 2H), 2.25 (s, 6H), 1.94 (s, 3H); MS m/z 468 (M+1); Anal.
Calc'd for C22H20F3NιO3S2 C, 56.52; H, 4.31; N, 3.00; found: C, 56.19; H, 4.23; N, 2.91.
Example 8
Synthesis of {3-Methoxy-5-methyl-4-r4-methyl-2-(4-trifluoromethyl-phenyl)- thiaζol-5-ylmethylsulfanyll-phenoxyl-acetic acid (Compound 8)
Figure imgf000052_0001
Preparation of 3-Methoxy-5-methyl-4-thiocyanato-phenol (compound 8A)
Figure imgf000053_0001
8A
Compound 8A was prepared from 3-methoxy-5-methyl-phenol in a similar manner as described for compound 3A to give, after recrystalisation from CHCl /hexanes, 1.9 g (13%) of the title compound. 400 MHz Η NMR (DMSO-d6) δ 10.14 (s, IH), 6.39 (s, 2H), 3.79 (s, 3H), 2.35 (s, 3H); MS m/z 196 (M+1).
Preparation of (3-Methoxy-5-methyl-4-thiocyanato-phenoxy)-acetic acid methyl ester (compound 8B)
Figure imgf000053_0002
8B
Compound 8B was prepared from compound 8A in a similar manner as described for compound 3B to give 2.2 g (87%) of the title compound pure, enough for subsequent use. 400 MHz Η NMR (DMSO- ) δ 6.60 (s, 2H), 4.84 (s, 2H), 3.85 (s, 3H), 3.66 (s, 3H), 2.40 (s, 3H); MS m/z 268 (M+1). Preparation of (4-Mercapto-3-methoxy-5-methyl-phenoxy)-acetic acid methyl ester (compound 8C)
Figure imgf000054_0001
8C
Compound 8C was prepared from compound 8B in a similar manner as described for compound 3C to give, after purification by flash column chromatography (gradient elution: 5% EtOAc/hexanes to 50% EtOAc/hexanes), the title compound (0.82 g, 45%) as a white solid. 400 MHz Η NMR (DMSO- ) δ 6.46 (s, IH), 6.42 (s, IH), 4.71 (s, 2H), 4.24 (s, IH), 3.76 (s, 3H), 3.64 (s, 3H), 2.16 (s, 3H); MS m/z 243 (M+1).
Preparation of {3-Methoxy-5-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)- thiaζol-5-ylmethylsulfanyl]-phenoxy}-acetic acid methyl ester (compound 8D)
Figure imgf000054_0002
8D
Compound 8C and 5-chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole were coupled in a similar manner as described for compound IF to provide, after purification by flash column chromatography (gradient elution: 5% EtOAc hexanes to 50% EtOAc/hexanes), the title compound (0.71 g, 69%) as a yellow solid. IR (thin film) cm"1: 1766, 1325; 400 MHz 1H NMR (DMSO- ) δ 7.97 (d, 2H, 7 = 8.1 Hz), 7.75 (d, 2H, 7 = 8.1 Hz), 6.42 (s, IH), 6.37 (s, IH), 4.75 (s, 2H), 4.09 (s, 2H), 3.74 (s, 3H), 3.63 (s, 3H), 2.12 (s, 3H), 2.01 (s, 3H); MS m/z 498 (M+1); Anal. Calc'd for C23H22F3N,O4S2 C, 55.52; H, 4.46; N, 2.82; found: C, 55.30; H, 4.44; N, 2.73.
Preparation of {3-Methoxy-5-methyl-4-[4-methyI-2-(4-trifluoromethyl-phenyl)- thiaζol-5-ylmethylsulfanyl]-phenoxy}-acetic acid (Compound 8)
Compound 8D was saponified in the same manner as described for compound IF to give, after recrystalisation from CHCl3/hexanes, the title compound (0.14 g, 49%) as a pale yellow solid, mp 164-165 °C; IR (thin film) cm"1: 1726, 1323; 400 MHz Η NMR (DMSO-dβ) δ 7.97 (d, 2H, 7 = 8.1 Hz), 7.75 (d, 2H, 7 = 8.1 Hz), 6.41 (s, IH), 6.35 (s, IH), 4.62 (s, 2H), 4.08 (s, 2H), 3.73 (s, 3H), 2.12 (s, 3H), 2.01 (s, 3H); MS m/z 484 (M+1); Anal. Calc'd for C22H20F3N,O4S2 C, 54.65; H, 4.17; N, 2.90; found: C, 54.12; H, 4.06; N, 2.69.
Example 9
Synthesis of {2-Isopropyl-5-methyl-4-r4-methyl-2-(4-trifluoromethyl-phenyl)- thiazol-5-ylmethylsulfanyll-phenoxyl-acetic acid (Compound 9)
Figure imgf000055_0001
Preparation of 2-Isopropyl-5-methyl-4-thiocyanato-phenol (compound 9A)
Figure imgf000056_0001
9A
The title compound was prepared in a manner analogous to compound 3A. 400 MHz Η NMR (DMSO-dβ) δ 8.9 (s(br), IH), 7.37 (s, IH), 6.86 (s, IH), 3.23 (m, IH), 2.38 (s, 3H), 1.12 (d, 6H, J = 7.1 Hz); MS m/z 208 (M+1).
Preparation of (2-Isopropyl-5-methyl-4-thiocyanato-phenoxy)-acetic acid methyl ester (compound 9B)
Figure imgf000056_0002
9B
The title compound was prepared from compound 9A in a manner analogous to compound 3B. 400 MHz Η NMR (DMSO-.4) δ 7.41 (s, IH), 6.86 (s, IH), 4.86 (s, 2H), 3.65 (s, 3H), 3.20 (m, IH), 2.38 (s, 3H), 1.1 (d, 6H, J = 7.2 Hz); MS m/z 280 (M+1).
Preparation of (2-Isopropyl-4-mercapto-5-methyl-phenoxy)-acetic acid methyl ester (compound 9C)
Figure imgf000056_0003
The title compound was prepared from compound 9B in a manner analogous to compound 3C. 400 MHz Η NMR (DMSO- ) δ 7.37 (s, IH), 6.86 (s, IH), 5.0 (s, IH), 4.85 (s, 2H), 3.68 (s, 3H), 3.23 (m, IH), 2.28 (s, 3H), 1.12 (d, 6H, J = 6.8 Hz); MS m/z 255 (M+1).
Preparation of {2-Isopropyl-5-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)- thiazol-5-ylmethylsulfanyl]-phenoxy}-acetic acid methyl ester (compound 9D)
Figure imgf000057_0001
9D
The title compound was prepared from compound 9C in a manner analogous to example IF. 400 MHz Η NMR (DMSO- ) δ 7.98 (d, 2H, J = 8 Hz), 7.76 (d, 2H, J = 8 Hz), 6.94 (s, IH), 6.74 (s, IH), 4.76 (s, 2H), 4.17 (s, 2H), 3.63 (s, 3H), 3.1 (m, IH), 2.24 (s, 3H), 1.93 (s, 3H), .96 (d, 6H, J = 7.2 Hz); MS m/z 510 (M+1).
Preparation of {2-Isopropyl-5-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)- thiazol-5-ylmethylsulfanyl]-phenoxy}-acetic acid (Compound 9)
The title compound was prepared from compound 9D in a manner analogous to compound 1. mp 168-171 °C; IR (thin film) cm"1: 2956, 2583, 1749, 1326; 400 MHz Η NMR (DMSO- 6) δ 12.94 (s(br), IH), 8.00 (d, 2H, J = 8.4 Hz), 7.78 (d, 2H, J = 8.4 Hz), 6.95 (s, IH), 6.74 (s, IH), 4.66 (s, 2H), 4.18 (s, 2H), 3.1 1 (m, IH), 2.27 (s, 3H), 1.95 (s, 3H), 0.98 (d, 6H, J = 7.2 Hz); MS m/z 496 (M+1). Anal. Calc'd for C24H24F3NO3S2 C, 58.17; H, 4.88; N, 2.83; found: C, 57.73; H, 4.62; N, 2.75.
Example 10 Synthesis of {2,6-Diisopropyl-4-r4-methyl-2-(4-trifluoromethyl-phenyl)-thiaζol-5- ylmethylsulfanyll-phenoxyl-acetic acid (Compound 10)
Figure imgf000058_0001
10 Preparation of 2,6-Diisopropyl-4-thiocyanato-phenol (compound 10A)
Figure imgf000058_0002
10A
The title compound was prepared in a manner analogous to compound 3A. 400 MHz Η NMR (DMSO- δ 8.8 (s, IH), 7.22 (s, 2H), 3.25 (m, 2H), 1.1 (d, 12H, J = 7.2 Hz); MS m/z 236 (M+1).
Preparation of (2,6-Diisopropyl-4-thiocyanato-phenoxy)-acetic acid methyl ester (compound 10B)
Figure imgf000058_0003
The title compound was prepared from compound 10A in a manner analogous to compound 3B. 400 MHz Η NMR (DMSO-d6) δ 7.37 (s, 2H), 4.44 (s, 2H), 3.68 (s, 3H), 3.23 (m, 2H), 1.12 (d, 12H, J = 6.8 Hz); MS m/z 308 (M+1).
Preparation of (2,6-Diisopropyl-4-mercapto-phenoxy)-acetic acid methyl ester (compound 10C)
Figure imgf000059_0001
10C
The title compound was prepared from compound 10B in a manner analogous to compound 3C. 400 MHz Η NMR (DMSO-d6) δ 7.37 (s, 2H), 4.88 (s, IH) 4.49 (s, 2H), 3.7 (s, 3H), 3.23 (m, 2H), 1.12 (d, 12H, J = 6.8 Hz); MS m/z 283(M+1).
Preparation of{2,6-Diisopropyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)- thiaζol-5-ylmethylsulfanyl]-phenoxy}-acetic acid methyl ester (compound 10D)
Figure imgf000059_0002
10D The title compound was prepared from compound 10C in a manner analogous to compound IF. 400 MHz Η NMR (DMSO- 6) δ 7.97 (d, 2H, J = 8.4 Hz), 7.76 (d, 2H, 8.4 Hz), 7.00 (s, 2H), 4.3 (m, 4H), 3.66 (s, 3H), 3.13 (m, 2H), 2.04 (3H), 1.01 (d, 12H, J = 7.2 Hz); MS m/z 538 (M+1 ).
Preparation of {2,6-Diisopropyl-4-[4-methyI-2-(4-trifluoromethyl-phenyl)- thiaζol-5-ylmethylsulfanyl]-phenoxy}-acetic acid (Compound 10)
The title compound was prepared from compound 10D in a manner analogous to compound 1. mp 161-163 °C; IR (thin film) cm"1: 2966, 1739, 1438, 1323; 400 MHz Η NMR (DMSO- ) δ 12.93 (s(br), IH), 7.8 (d, 2H, J = 8 Hz), 7.76 (d, 2H, J = 8 Hz), 7.00 (s, 2H), 4.32 (s, 2H), 4.2 (s, 2H), 3.12 (m, 2H), 2.03 (s, 3H), 1.01 (d, 12H, J = 7.2 Hz); MS m/z 524 (M+1). Anal. Calc'd for C26H28F3NO3S2 C, 59.64; H, 5.39; N, 2.67; found: C, 58.82; H, 5.54; N, 2.48.
Example 11
Synthesis of 2-Methyl-2-|4-f4-methyl-2-(4-trifluoromethyl-phenyl)-thiaζol-5- ylmethylsulfanyll-phenyll-propionic acid (Compound 11)
Figure imgf000060_0001
11
Preparation of 2-(4-BenzyIoxy-phenyl)-2-methyI-propionic acid methyl ester (HA)
Figure imgf000060_0002
1). (4-Benzyloxy-phenyl)-acetic acid (lOg, 41 mmol) was dissolved in MeOH (100 mL) and was then treated with H2SO (5 mL). The reaction mixture was refluxed overnight. MeOH was evaporated and the residue was diluted with water and ether. Layers were separated and the aqueous layer was extracted with ether (2x30mL). The combined organics were dried with MgSO and condensed to afford the product (10.24g, 97%) as white crystals. MS: 257 (M+1) +
2). To a suspension of NaH (2.34g, 58.5 mmol) in THF (150 mL) was added a solution of the above ester (5.0g, 19.8 mmol) in THF (50 mL) followed by dropwise addition of methyl iodide (6.65g, 47 mmol). The mixture was stirred at RT overnight. Water (100 mL) was added and the layers were separated. The aqueous layer was extracted with ether (2x50mL). The combined organics was dried with MgSO4 and evaporated to give a yellow solid as the desired product 11A (4.37g, 79%). MS: 285 (M+1 ) +
Preparation of 2-(4-Dimethylthiocarbamoyloxy-phenyl)-2-methyl-propionic acid methyl ester (compound 11B)
Figure imgf000061_0001
11B
1). Compound 11 A (2.08g, 7.31 mmol) was dissolved in MeOH (50 mL) and was subjected to hydrogenation conditions catalyzed by 20% Pd/C. After 17 h, the reaction mixture was filtered and the filtrate was evaporated to give the desired product as a white solid (1.85g, 100%)
2). The phenol compound obtained from above (1.0g, 5.15 mmol) was dissolved in dioxane (10 mL) followed by addition of Et3N (1.04g, 10.3 mmol), DMAP (63mg, 0.52 mmol), and dimethyl thiocarbamoyl chloride (0.76g, 6.18 mmol). The reaction mixture was refluxed overnight. After cooling down to RT, the reaction mixture was diluted with EtOAc (100 mL) and H2O (100 mL). Layers were separated and the aqueous layer was extracted with EtOAc (2x50mL). Combined organics was dried over MgSO and condensed to give the desired product 1 IB as a brown oil (1.61 g,
100%)
MS: 282 (M+1 ) +
Preparation 2-(4-Mercapto-phenyl)-2-methyl-propionic acid methyl ester (compound 11 C)
Figure imgf000062_0001
11C
1). Compound 11B (1.61 g, 5.15 mmol) in tetradecane (20 mL) was heated to reflux overnight. After cooling down to RT, solvent was decanted out and the residue was washed with hexane. It was then taken up to EtOAc (100 mL) and washed with H2O, dried over MgSO and condensed to give the desired product as a tan solid (0.15g). More crystals (0.39g) were collected from the tetradecane solution that was first decanted. Total yield of the reaction was 34% (0.54g). MS: 282 (M+1) +
2). The above product (0.54g, 1.92 mmol) was immediately dissolved in MeOH (5 mL) and was treated with NaOMe (0.114g, 2.1 Immol). The reaction mixture was heated to reflux overnight and MS indicated the presence of the desired product 11C. The reaction was cooled to RT and used for next step without purification. MS: 209 (M-1) + Preparation 2-Methyl-2-{4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethy!sulfanyl]-phenyl}-propionic acid (Compound 11)
1 ). To the above mixture was added a solution of the chloride IB (0.25g, 0.86 mmol) in MeOH (10 mL) and the resulting solution was heated to reflux overnight. MeOH was then removed via rotavap and the residue was dissolved in EtOAc (50mL) and washed with H2O. Solvent was dried over MgSO and condensed to give the crude product as an oil. It was purified by silica gel chromatography eluted with 10% EtOAc Hexanes to afford the pure product (0.22g, 24%) as a yellow oil. MS: 466 (M+1 ) +
2). The above methyl ester (0.22g, 0.4 mmol) dissolved in THF (10 mL) and treated with LiOH.H2O (O.lg, 2 mmol). After reflux overnight, the reaction mixture was cooled to RT and neutralized with aq. HC1 (I N). Solvent was removed and the solid was filtered off and washed with EtOAc. The filtrate was dried over MgSO and condensed to give the desired product compound 11 as a yellow solid (0.17g, 96%). MS: 452 (M+l)+, CHN: Calc'd: C 58.52, H 4.46, N 3.10; Found: C 58.65, H 4.33, N 3.04.
Example 12 Synthesis of 2-{4-r4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyll-phenyll-cvclopropanecarboxylic acid (Compound 12)
Figure imgf000063_0001
12 Preparation of 2-Phenyl-cyclopropanecarboxylic acid methyl ester (12A)
Figure imgf000064_0001
12A
2-Phenyl-cyclopropanecarboxylic acid (5g, 30.86 mmol) was dissolved in MeOH (100 mL) and was then treated with H2SO (2 mL). The reaction mixture was refluxed overnight. MeOH was evaporated and the residue was diluted with water and ether. Layers were separated and the aqueous layer was extracted with ether (2x30mL). The combined organics were dried with MgSO4 and condensed to afford the product compound 12A (5.3g, 97%) as white crystals. MS: 177 (M+1 ) +
Preparation of 2-(4-Chlorosulfonyl-phenyl)-cyclopropanecarboxylic acid methyl ester (compound 12B)
Figure imgf000064_0002
12B
Chlorosulfonic acid (10 mL) was cooled to 0°C. Then compound 12A (2.0g, 11.36 mmol) was added over 30 min. The mixture was stirred at RT for 3h and was poured into ice (lOOg). The cloudy solution was extracted with ether (2xl00mL). The extracts were dried with magnesium sulfate and concentrated to give a brown oil which was passed through a short pad of silica gel to afford the desired product 12B (2.96g, 95%) as white plates. NMR (Η, CDC13): δ 7.95 (2H, m), 7.29 (2H, m), 3.74 (3H, s), 2.68 (IH, m), 2.03
(IH, m), 1.78 (IH, m), 1.41 (IH, m).
Preparation of 2-(4-Mercapto-phenyl)-cyclopropanecarboxylic acid methyl ester (compound 12C)
Figure imgf000065_0001
The above product 12B was refluxed with tin powder (4.4g, 37.7 mmol) in MeOH (10 mL) and 4M HCl/dioxane (10 mL). After 3h, the reaction mixture was poured into ice with CH2C12 (100 mL). The phases were separated and the aqueous layer was extracted with CH2C1 (2x50mL). The combined organic layers were dried with magnesium sulfate, filtered and evaporated to give the thiol compound 12C as a yellow oil (1.06g, 70%). MS: 207 (M-1) +
Preparation of 2-[4-(4-Methyl-2-p-tolyl-thiazol-5-ylsulfanyl)-phenyl]- cyclopropanecarboxylic acid methyl ester (compound 12D)
Figure imgf000065_0002
12D
Compound 12C (1.06g, 5.09 mmol) was dissolved in acetonitrile (80 L) with the chloride IB (1.3g, 4.4 mmol) and Cs2CO3 (3.3g, 1.07 mmol). The reaction mixture was stirred at RT overnight. Ether (50 mL) and H2O were added and stirring was continued for another 5 min. The layers were separated and the aqueous layer was extracted with ether (2x100 mL). The combined organics was dried over MgSO and concentrated to an oil. The crude product was purified by column chromatography eluted with EtOAc and hexanes to give the desired product, compound 12D as a thick yellow oil (l .l g , 47%). MS: 464 (M+1 ) +
Preparation of l-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenyl}-cyclopropanecarboxylic acid (Compound 12)
To the solution of the above methyl ester, compound 12D (0.38g, 0.82 mmol) in MeOH (7mL) and THF (7mL) was added LiOH.H2O (69mg, 1.64 mmol). After refluxing overnight, the solution was cooled to RT and solvents were removed by rotavap. The residue was dissolved in water and neutralized with IN HCl. The cloudy solution was extracted with EtOAc (3x50 mL) and the extracts were dried with MgSO , and concentrated. The crude product was purified by chromatography to afford a yellow solid, which was further washed with ether to yield the desired product as yellowish crystals (116mg, 31%). MS: 450 (M+1 )+.
Example 13
Synthesis of l-{4-r4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanvn-phenyll-cyclopropanecarboxylic acid (Compound 13)
Figure imgf000066_0001
13 Preparation of 1-Phenyl-cyclopropanecarboxylic acid methyl ester (compound 13A)
Figure imgf000067_0001
13A
Compound 13A was made following the procedure in Example 12A, by replacing 2- Phenyl-cyclopropanecarboxylic acid with compound 1 -Phenyl- cyclopropanecarboxylic acid. Compound 13A was prepared in quantitative yield. MS: 177 (M+1)+.
Preparation of l-(4-Chlorosulfonyl-phenyl)-cyclopropanecarboxylic acid methyl ester (compound 13B)
Figure imgf000067_0002
cιo2s
13B
Compound 13B was prepared analogously to compound 12B. 57% yield. MS: 239 (M-C1) +.
Preparation of l-(4-Mercapto-phenyl)-cyclopropanecarboxylic acid methyl ester (compound 13C)
Figure imgf000067_0003
13C
Compound 13C was prepared analogously to compound 12C. Preparation of l-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenyl}-cyclopropanecarboxylic acid methyl ester (compound 13D):
Figure imgf000068_0001
13D
Compound 13D was prepared analogously to compound 12D using the crude product compound 13C. Yield was 12% in 2 steps. MS for 15D: 464 (M+l) +
Preparation of l-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenyl}-cyclopropanecarboxy!ic acid (Compound 13):
Compound 13 was prepared analogously to compound 12. Compound 13 was prepared in 54% yield. MS: 450 (M+1 ) +.
Example 14 Synthesis of l-{4-r4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyll-phenyll-cvclopentanecarboxylic acid (Compound 14)
Figure imgf000068_0002
Preparation of 1-Phenyl-cyclopentanecarboxylic acid methyl ester (compound 14A)
Figure imgf000069_0001
Compound 14A was made following the procedure in Example 12A, by replacing 2- Phenyl-cyclopropanecarboxylic acid with 1-Phenyl-cyclopentanecarboxylic acid. Compound 14A was prepared in quantitative yield. MS: 205 (M+l) +.
Preparation of l-(4-Chlorosulfonyl-phenyl)-cyclopentanecarboxylic acid methyl ester (compound 14B)
Figure imgf000069_0002
14B Compound 14B was prepared analogously to compound 12B. 50% yield. MS: 267
(M-C1)+:
Preparation of l-(4-Mercapto-phenyl)-cyclopentanecarboxylic acid methyl ester(compound 14C)
Figure imgf000069_0003
14C Compound 14C was prepared analogously to compound 12C.
Preparation of l-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenyl}-cyclopentanecarboxylic acid methyl ester(compound 14D)
Figure imgf000070_0001
14D Compound 14D was prepared analogously to compound 12D using the crude product compound 14C. Yield was 31 % in 2 steps. MS for 14D: 492 (M+l) +
Preparation of l-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenyl}-cyclopentanecarboxylic acid (Compound 14)
Compound 14 was prepared analogously to compound 12 in 80% yield. MS: 478
(M+l)+.
Example 15
Synthesis of 4-Methyl-4-|4-r4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyll-phenyli-pentanoic acid (Compound 15)
Figure imgf000070_0002
15 Preparation of 4-Methyl-4-phenyl-pentanoic acid methyl ester (compound 15A)
Figure imgf000071_0001
Compound 15A was prepared by hydrogenation of the corresponding crotonate catalyzed by Pd/C (10%) in 93% yield. MS: 221 (M+l)+.
Preparation of 4-(4-Chlorosulfonyl-phenyl)-4-methyl-pentanoic acid ethyl ester(compound 15B)
Figure imgf000071_0002
cιo2s
15B
Compound 15B was prepared analogously to compound 12B in 85% yield. MS: 283 (M-C1) +.
Preparation of 4-(4-Mercapto-phenyl)-4-methyl-pentanoic acid ethyl ester (compound 15C)
Figure imgf000071_0003
15C
Compound 15C was prepared analogously to compound 12C. Preparation of 4-Methyl-4-{4-[4-methyl-2-(4-trifluoromethyI-phenyl)-thiazol-5- ylmethylsulfanyl]-phenyl}-pentanoic acid ethyl ester (compound 15D)
Figure imgf000072_0001
15D
Compound 15D was prepared analogously to compound 12D using the crude product compound 15C. Yield was 21 % in 2 steps. MS for 17D: 508 (M+l)+.
Preparation of 4-Methyl-4-{4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazoI-5- ylmethylsulfanyl]-phenyl}-pentanoic acid (Compound 15)
Compound 15 was prepared analogously to compound 12. Compound 15 was prepared in 38% yield. MS: 480 (M+l)+.
Example 16
Synthesis of 3-|4-r4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyll-phenoxyl-propionic acid (Compound 16)
Figure imgf000072_0002
Preparation of 3-Phenoxy-propionic acid methyl ester (compound 16A)
Figure imgf000073_0001
16A
Compound 16A is commercially available from Aldrich of Milwaukee, Wisconsin.
Preparation of 3-(4-Chlorosulfonyl-phenoxy)-propionic acid methyl ester (compound 16B)
Figure imgf000073_0002
16B
Compound 16B was prepared analogously to compound 12B. 69% yield.
Preparation of 3-(4-Mercapto-phenoxy)-propionic acid methyl ester (compound 16C)
Figure imgf000073_0003
16C
Compound 16C was prepared analogously to compound 12C.
Preparation of 3-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy}-propionic acid methyl ester (compound 16D)
Figure imgf000073_0004
16D Compound 16D was prepared analogously to compound 12D using the crude product compound 16C. Compound 16D was prepared in 49% yield. MS: 21 1 (M-l)+.
Synthesis of 3-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethyIsulfanyl]-phenoxy}-propionic acid (Compound 16)
Compound 16 was prepared by treating the ester with concentrated HBr in 17% yield.
MS: 454 (M+1 )+.
Example 17
Synthesis of 2-l3-Methoxy-4-r4-methyl-2-(4-trifluoromethyl-phenyl)-thiazoI-5- ylmethylsulfanvn-phenyl)-2-methyl-propionic acid (Compound 17)
Figure imgf000074_0001
17
Preparation of 2-(3-Methoxy-phenyl)-2-methyl-propionic acid methyl ester (Compound 17A)
Figure imgf000074_0002
17A
17A was prepared analogously to compound 11A. MS: 209 (M+l)+. Preparation of 2-(4-Chlorosulfonyl-3-methoxy-phenyl)-2-methyl-propionic acid methyl ester (Compound 17B)
Figure imgf000075_0001
17B 17B was prepared analogously to compound 12B. 39% yield. MS: 271 (M-C1)+.
Preparation of 2-(4-Mercapto-3-methoxy-phenyl)-2-methyl-propionic acid methyl ester (Compound 17C)
Figure imgf000075_0002
17C
17C was prepared analogously to compound 12C. Used as unpurified oil. MS: 239 (M-l)+.
Preparation of 2-{3-Methoxy-4-[methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-2-methyl-propionic acid methyl ester (Compound 17D)
Figure imgf000075_0003
17D Compound 17D was prepared analogously to compound 12D. Yield was 12% after flash column purification. MS: 496 (M+l)+.
Preparation of 2-{3-Methoxy-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenyl}-2-methyl-propionic acid (Compound 17)
Compound 17 was prepared analogously to compound 12. Compound 17 was prepared in 50% yield. MS: 482 (M+l)+.
Example 18
Synthesis of 3-Methyl-3-(4-r4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyll-phenyll-butyric acid (Compound 18)
Figure imgf000076_0001
18 Preparation of 3-Methyl-3-phenyl-butyric acid methyl ester (Compound 18A
Figure imgf000076_0002
18A
18A was prepared analogously to compound 11A. 96% yield. MS: 179 (M+l)+ Preparation of 2-Methyl-2-phenyl-propan-l-ol (Compound 18B)
Figure imgf000076_0003
18B 18B was prepared analogously to compound 1A. Quantitative yield. MS: 133 (M- H2O)+. Preparation of 3-Methyl-3-phenyl-butyronitrile (Compound 18C)
Figure imgf000077_0001
18C
Methane sulfonyl chloride was added to a stirred solution of compound 18B dissolved in CH2C12 and triethyl amine at 0°C. The mixture was stirred at RT for 4 hr. It was then diluted with CH2C12 and washed with 1 x sat. NFLC1, 1 x brine, dried (MgSO ) and the solvent removed in vacuo to give 2.68 g (88%) of the methanesulfonated compound.
The methanesulfonated intermediate obtained from above was dissolved in DMSO and added with sodium cyanide. The mixture was heated at 100°C overnight. After cooling down to RT, the reaction mixture was diluted with water and layered with ether. The layers were separated and the aqueous layer extracted with ether. The combined organics were dried over MgSO and condensed to give the crude product as an oil. It was purified by silica gel chromatography eluted with 10% EtOAc/Ηexanes to afford the desired compound 18C as a clear oil (0.26 g, 26%). MS: 160 (M+1 )+.
Preparation of 4-(2-Cyan-l, l-dimethyl-ethyl)-benzenesulfonyl chloride (Compound 18D)
Figure imgf000077_0002
18D
18D was prepared analogously to compound 12B. 71 % yield. MS: 222 (M-C1)+. Preparation of 3-(4-Mercapto-phenyl)-3-methyl-butyronitrile (Compound 18E)
HS xY 18E 18E was prepared analogously to compound 12C. 92% yield. MS: 252 (M+l)+.
Preparation of 3-Methyl-3-{ 4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenyl}-butyronitrile (Compound 18F)
Figure imgf000078_0001
18F Compound 18F was prepared analogously to compound 12D. Yield was 20% after flash column purification. MS: 447 (M+l)+.
Preparation of 3-Methyl-3-{ 4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenyl}-butyric acid (Compound 18)
Compound 18F stirred in 2-methoxy ethanol was added with 30 % NaOH solution. The mixture was heated at reflux overnight. The solvent was removed in vacuo to give the crude product as a dark oil. It was purified by silica gel chromatography eluted with 15% EtOAc/Hexanes to afford the desired compound 18 as a yellow solid (0.014 g, 8%). MS: 466 (M+l)+.
Example 19 Synthesis of 3-{2,4-Dimethoxy-5-r4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol- 5-ylmethylsulfanvn-phenyl)-propionic acid (Compound 19)
Figure imgf000078_0002
19 Preparation of 3-(2,4-Dimethoxy-phenyl)-propionic acid ethyl ester(Compound 19A)
Figure imgf000079_0001
19A
2,4-Dimethoxybenzaldehyde in THF was added to a stirred solution of sodium hydride and triethyl phosphonoacetate in THF at 0°C. After 15 min., water was added and the mixture was stirred at RT for 2 hr. The layers were separated and the aqueous layer was extracted with ether. The combined organics was dried with MgSO4 and evaporated to a yellow oil in quantitative yield. MS: 237 (M+1 )+.
Compound 19A was then prepared by hydrogenation of the unsaturated oil catalyzed by Pd/C (10%) in 88% yield. MS: 239 (M+l)+.
Preparation of 3-(5-Chlorosulfonyl-2,4-dimethoxy-phenyl)-propionic acid ethyl ester (Compound 19B)
Figure imgf000079_0002
19B
19B was prepared analogously to compound 12B. 52% yield. MS: 301 (M-C1)+.
Preparation of 3-(5-Mercapto-2,4-dimethoxy-phenyI)-propionic acid ethyl ester (Compound 19C)
Figure imgf000079_0003
19C 19C was prepared analogously to compound 12C. Used as unpurified oil. MS: 271 (M+l )+.
Preparation of 3-{2,4-Dimethoxy-5-[4-methyl-2-(4-trifluoromethyl-phenyl)- thiazol-5-ylmethylsulfanyl]-phenyl}-propionic acid ethyl ester (Compound 19D)
Figure imgf000080_0001
19D Compound 19D was prepared analogously to compound 12D. Yield was 45% after flash column purification. MS: 526 (M+l)+.
Preparation of 3-{2,4-Dimethoxy-5-[4-methyl-2-(4-trifluoromethyl-phenyl)- thiazol-5-ylmethylsulfanyl]-phenyl}-propionic acid (Compound 19)
Compound 19 was prepared analogously to compound 12. Compound 19 was prepared in 54% yield. MS: 498 (M+l )+.
Example 20
Synthesis of 3-{2.5-Dimethoxy-4-F4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol- 5-ylmethylsulfanyll-phenvπ-propionic acid (Compound 20)
Figure imgf000080_0002
20
Preparation of 3-(2,5-Dimethoxy-phenyl)-propionic acid ethyl ester (Compound
20A)
Figure imgf000081_0001
20A
20A was prepared analogously to compound 19A. 94% yield. MS: 239 (M+l)+.
Preparation of 3-(4-Chlorosulfonyl-2,5-dimethoxy-phenyl)-propionic acid ethyl ester (Compound 20B)
Figure imgf000081_0002
20B
20B was prepared analogously to compound 12B. 88% yield. MS: 301 (M-C1)+.
Preparation of 3-(4-Mercapto-2,5-dimethoxy-phenyl)-propionic acid ethyl ester (Compound 20C)
Figure imgf000081_0003
20C 20C was prepared analogously to compound 12C. Used as unpurified oil. MS: 271
(M+l)+. Preparation of 3-{2,5-Dimethoxy-4-[4-methyI-2-(4-trifluoromethyl-phenyl)- thiazol-5-ylmethylsulfanyl]-phenyl}-propionic acid ethyl ester (Compound 20D)
Figure imgf000082_0001
20D
Compound 20D was prepared analogously to compound 12D. Yield was 26% after flash column purification. MS: 526 (M+l)+.
Preparation of 3-{2,5-Dimethoxy-4-[4-methyl-2-(4-trifluoromethyl-phenyl)- thiazol-5-y!methylsulfanyl]-phenyl}-propionic acid (Compound 20)
Compound 20 was prepared analogously to compound 12. Compound 20 was prepared in 98% yield. MS: 498 (M+l)+.
Example 21
Synthesis of {2,4-Dimethoxy-5-r4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanylll-acetic acid (Compound 21)
Figure imgf000082_0002
21 Preparation of (2,4-Dimethoxy-phenyl)-acetic acid methyl ester (Compound
21A)
Figure imgf000083_0001
21A
21A was prepared analogously to compound 12A. Quantitative yield. MS: 21 1
(M+l)+.
Preparation of (5-Chlorosulfonly-2, 4-dimethoxy-phenyl)-acetic acid methyl ester (Compound 21B)
Figure imgf000083_0002
21B
21B was prepared analogously to compound 12B. 83% yield. MS: 307 (M+l)+.
Preparation of (5-Mercapto-2, 4-dimethoxy-phenyl)-acetic acid methyl ester (Compound 21 C)
Figure imgf000083_0003
21C
21C was prepared analogously to compound 12C. Used as unpurified oil. MS: 243
(M+l)+. Preparation of {2,4-Dimethoxy-5-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol- 5-ylmethylsulfanyl]-acetic acid methyl ester (Compound 21D)
Figure imgf000084_0001
21D
Compound 21D was prepared analogously to compound 12D. Yield was 25% after flash column purification. MS: 498 (M+l)+.
Preparation of {2,4-Dimethoxy-5-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol- 5-ylmethylsulfanyl]-acetic acid (Compound 21)
Compound 21 was prepared analogously to compound 12. Compound 21 was prepared in 82% yield. MS: 484 (M+l)+.
Example 22
Synthesis of 3-{4-r4-Methtyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy1- phenvU-2-pyrrol-l-yl-propionic acid (Compound 22)
Figure imgf000084_0002
22 Preparation of 3-{4-[4-Methtyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethoxy]-phenyl}-2-pyrrol-l-yl-propionic acid methyl ester (Compound 22A)
Figure imgf000085_0001
22A
Compound 22A was prepared according to the method of example IF utilizing 3-(4- hydroxy-phenyl)-2-pyrrol-l-yl-propionic acid methyl ester. MS: 501 (M+l)+. Preparation of 3-{4-[4-Methtyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethoxy]-phenyl}-2-pyrrol-l-yl-propionic acid (Compound 22)
Compound 22 was prepared according to the method of example 1 utilizing compound 22A. MS: 487 (M+l )+.
Example 23 Synthesis of 3-|4-r4-Methtyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy1- phenyll-2-phenyl-propionic acid (Compound 23)
Figure imgf000085_0002
23 Prepa ration of 3-{4-[4-Methtyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethoxy]-phenyl}-2-phenyl-propionic acid methyl ester (Compound 23A)
Figure imgf000086_0001
23A
Compound 23A was prepared according to the method of example IF utilizing 3-(4- hydroxy-phenyl)-2-phenylpropionic acid methyl ester. MS: 512 (M+l)+.
Preparation of 3-{4-[4-Methtyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethoxy]-phenyl}-2-phenyl-propionic acid (Compound 23)
Compound 23 was prepared according to the method of example 1 utilizing compound 23A. MS: 498 (M+1 )+.
Example 24 Synthesis of 3-{4-r4-Methtyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl1-phenyl)-2-pyrrol-l-yl-propionic acid (Compound 24)
Figure imgf000086_0002
24
Preparation of 3-(4-Dimethylcarbamoylsulfanyl-phenyl)-2-pyrrol-l-yl-propionic acid methyl ester (Compound 24A)
Figure imgf000087_0001
24A
3-(4-Hydroxy-phenyl)-2-phenylpropionic acid methyl ester, Et N, 4-dimethylamino- pyridine and dimethyl thiocarbamoyl chloride in dioxane was refluxed for 16h. After removing most of solvent, the mixture was partition between ethyl acetate and water. The organic layer was separated, washed with water, dried, filtered and evaporated to afford 4-dimethylthiocarbamoyloxy-phenyl-propionic acid methyl ester, was used in the next step without further purification.
4-Dimethylthiocarbamoyloxy-phenyl-propionic acid methyl ester in THF was added drop wise into a refluxed solution of tetradecane, refluxed for another 3 hours. The solvent was decanted after cooling to room temperature, remaining oil washed several times with hexane. It was purified by flash column chromatography to afford compound 24A. MS: 333(M+1)+.
Preparation of 3-{4-[4-Methtyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenyl}-2-pyrrol-l-yl-propionic acid (Compound 24)
A solution of compound 24A in MeOH and NaOH was refluxed for 5 h. Then the 5- chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol was added and the mixture was refluxed for another hour. The solvent was removed and the crude product was purified by flash column chromatography to afford the compound 24.
MS: 503 (M+1 )+.
Example 25 Synthesis of 2-r5-(acetylamino)-2-methyl-4-({4-methyl-2-r4-
(trifluoromethyl)phenyll(1.3-thiazol-5-yl)lmethylthio)phenoxy1acetic acid (Compound 25)
Figure imgf000088_0001
25
Preparation of (2-amino-4-hydroxy-5-methylphenyl)thiocarbonitrile (Compound
25 A)
Figure imgf000088_0002
25A
To a mixture of 5-amino-2-methylphenol, sodium thiocyanate and sodium bromide in anhydrous methanol, and bromine in methanol was added dropwise over 30 minutes and allowed to stir at 0 °C for 1 h. Saturated sodium bicarbonate was added to bring pH 7, and the crude product was extracted with ethyl acetate. The combined organics were washed with brine, dried over anhydrous sodium sulfate, concentrated, and purified using normal phase chromatography to afford the title product. 400 MHz Η NMR (DMSO-de) δ 9.72 (s, IH), 7.10 (s, IH), 6.30 (s, IH), 5.59 (s, 2H), 1.98 (s, 3H).
Preparation of methyl 2-(3-amino-4-cyanothio-6-methylphenoxy)acetate (Compound 25B)
The title compound was prepared in the manner analogous to Example 3B with the product from example 25A methyl bromoacetate and cesium carbonate in acetonitrile. 400 MHz Η NMR (DMSO-d6) δ 7.20 (s, IH), 6.28 (s, IH), 5.71 (s, 2H), 4.77 (s, 2H), 3.71 (s, 3H), 2.04 (s, 3H).
Preparation of methyl 2-[5-(acetylamino)-4-cyanothio-2-methylphenoxy]acetate (Compound 25C)
Figure imgf000089_0001
25C
A mixture of the product from example 25B and acetic anhydride in pyridine was stirred at ambient temperature overnight, then ethyl acetate was added, washed with water, brine, dried over anhydrous sodium sulfate, concentrated to give 25C. 400 MHz Η NMR (DMSO-d6) δ 7.55 (s, IH), 6.81 (s, IH), 4.90 (s, 2H), 3.70 (s, 3H), 2.23 (s, 3H), 2.07 (s, 3H).
Preparation of methyl 2-[5-(acetylamino)-2-methyl-4-sulfanylphenoxy]acetate (Compound 25D)
Figure imgf000090_0001
A mixture of the product from example 25C, dithiothreitol and 0.2M potassium in methanol was refluxed for 1 h. After cooling, ethyl acetate was added, washed with water, brine, dried over anhydrous sodium sulfate, concentrated, and purified using normal phase chromatography to afford the title product. 400 MHz Η NMR (DMSO- d6) δ 9.26 (s, IH), 7.25 (s, IH), 7.20 (s, IH), 4.81 (s, 2H), 3.71 (s, 3H), 2.12 (s, 3H), 1.95 (s, 3H).
Preparation of methyl 2-[5-(acetylamino)-2-methyl-4-({4-methyl-2-[4- (trifluoromethyl)phenyl](l,3-thiazol-5-yl)}methylthio)phenoxy]acetate (Compound 25E)
Figure imgf000090_0002
25E
The title compound was prepared in the manner analogous to Example IF with the product from example 25D, 5-(chloromethyl)-4-methyl-2-[4-
(trifluoromethyl)phenyl]-l,3-thiazole and cesium carbonate in anhydrous acetonitrile. 400 MHz Η NMR (CDC13) δ 8.25 (s, IH), 7.92 (m, 3H), 7.68 (d, 2H), 4.70 (s, 2H), 4.00 (s, 2H), 3.81 (s, 3H), 2.20 (s, 3H), 2.12 (s, 3H), 2.02 (s,3H). MS m/z 524.83 (M+1). Preparation of 2-[5-(acetylamino)-2-methyl-4-({4-methyl-2-[4- (trifluoromethyl)phenyl](l,3-thiazol-5-yl)}methylthio)phenoxy]acetic acid (Compound 25)
The title compound was prepared in the manner analogous to Example 1 with the product from example 25E and lithium hydroxide monohydrate in tetrahydrofuran/water mixture (10: 1 ). MS m/z 510.75 (M+1 ).
Example 26
Synthesis of 2-r5-fluoro-2-methyl-4-((4-methyl-2-r4-(trifluoromethyl)phenyll(l, 3- thiazol-5-yl))methylthio)phenoxylacetic acid (Compound 26)
Figure imgf000091_0001
26
Preparation of 5-fluoro-2-methylphenol (compound 26A)
Figure imgf000091_0002
26A A mixture of 5-fluoro-2-methylphenylamine in concentrated sulfuric acid and water was heated until a clear solution was obtained, then cooled to 0 °C, a solution of sodium nitrite in water was added dropwise over 15 minutes, then poured into boiled saturated copper sulfate solution and heated for 15 minutes, cooled and extracted with ethyl acetate washed with water, brine, dried over anhydrous sodium sulfate, and concentrated to give 26A in good purity. 400 MHz Η NMR (CDC1 ) δ 7.05 (t, IH), 6.56 (m, 2H), 4.92 (s, IH), 2.19 (s, 3H).
Preparation of (2-fluoro-4-hydroxy-5-methylphenyl)thiocarbonitrile (Compound 26B)
Figure imgf000092_0001
The title compound was prepared in the manner analogous to Example 3A with the product from example 26A sodium thiocyanate, sodium bromide and bromine in anhydrous methanol. 400 MHz Η NMR (CDC13) δ 7.35 (d, IH), 6.67 (d, IH), 5.41 (s, lH), 2.22 (s, 3H).
Preparation of methyl 2-(4-cyanothio-5-fluoro-2-methylphenoxy)acetate (Compound 26C)
Figure imgf000092_0002
26C
The title compound was prepared in the manner analogous to Example 3B with the product from example 26B, methyl bromoacetate, and cesium carbonate in anhydrous acetonitrile. 400 MHz Η NMR (CDC13) δ 7.40 (d, IH), 6.55 (d, IH), 4.68 (s, 2H), 3.85 (s, 3H), 2.26 (s, 3H).
Preparation of methyl 2-(5-fluoro-2-methyl-4-suIfanylphenoxy)acetate (Compound 26D)
Figure imgf000093_0001
26D
The title compound was prepared in the manner analogous to Example 3C with the product from example 26C, dithiothreitol and 0.2M potassium dihydrogenphosphate in anhydrous methanol. 400 MHz Η NMR (DMSO-d6) δ 7.21 (d, IH), 6.88 (d, IH) 5.10 (s, IH), 4.84 (s, 2H), 3.69 (s, 3H), 2.10 (s, 3H).
Preparation of methyl 2-[5-fluoro-2-methyl-4-({4-methyl-2-[4-
(trifluoromethyl)phenyl](l,3-thiazol-5-yl)}methylthio)phenoxy]acetate (Compound 26E)
Figure imgf000094_0001
26E
The title compound was prepared in the manner analogous to Example IF with the product from example 26D, 5-(chloromethyl)-4-methyl-2-[4- (trifluoromethyl)phenyl]-l,3-thiazole, and cesium carbonate in 15 ml of anhydrous acetonitrile. 400 MHz Η NMR (CDC13) δ 7.98 (d, 2H), 7.65 (d, 2H), 7.12 (d, IH), 6.47 (d, IH), 4.63 (s, 2H), 4.12 (s, 2H), 3. 81 (s, 3H), 2.25 (s, 3H), 2.13 (s, 3H).
Preparation of 2-[5-fluoro-2-methyl-4-({4-methyl-2-[4- (trifluoromethyl)phenyl](l,3-thiazol-5-yl)}methylthio)phenoxy]acetic acid (Compound 26)
The title compound was prepared in the manner analogous to Example 1 with the product from example 26E, and lithium hydroxide monohydrate in tetrahydrofuran/water mixture (10:1). MS m/z 471.72(M+1).
Example 27
Synthesis of 2-r5-methoxy-2-methyl-4-({4-methyl-2-r4- (trifluoromethyl)phenyll(1.3-thiazol-5-yl)|methoxy)phenylthio1acetic acid (Compound 27)
Figure imgf000095_0001
27
Preparation of (4-hydroxy-5-methoxy-2-methylphenyl)thiocarbonitrile (Compound 27A)
Figure imgf000095_0002
27A The title compound was prepared in the manner analogous to Example 6B with 2- methoxy-5-methylphenol, sodium thiocyanate, sodium bromide, and bromine in methanol. 400 MHz Η NMR (DMSO-d6) δ 9.78 (s, IH), 7.20 (s, IH), 6.82 (s, IH), 3.79 (s, 3H), 2.32 (s, 3H).
Preparation of [5-methoxy-2-methyl-4-({4-methyl-2-[4- (trifluoromethyl)phenyl](l,3-thiazol-5-yl)}methoxy)phenyl]thiocarbonitrile (Compound 27B)
Figure imgf000095_0003
27B
The title compound was prepared in the manner analogous to Example IF with the product from example 27A, 5-(chloromethyl)-4-methyl-2-[4- (trifluoromethyl)phenyl]-l ,3-thiazole, and cesium carbonate in anhydrous acetonitrile. 400 MHz Η NMR (DMSO-d6) δ 8.14 (d, 2H), 7.85 (d, 2H), 7.29 (s, IH), 7.25 (s, IH), 5.40 (s, 2H), 3.80 (s, 3H), 2.50 (s, 3H), 2.47 (s, 3H).
Preparation of methyl 2-[5-methoxy-2-methyl-4-({4-methyl-2-[4- (trifluoromethyl)phenyl](l,3-thiazol-5-yl)}methoxy)phenylthio]acetate (Compound 27C)
Figure imgf000096_0001
27C
The product from example 27B, and sodium sulfide in anhydrous methanol was refluxed for 2 h, then cooled and concentrated under reduced pressure. The residue was dissolved in anhydrous acetonitrile, methyl bromoacetate and cesium carbonate were added. The reaction mixture was heated at 60 °C for 2 h, then cooled and filtered through Celite®, concentrated, purified using normal phase chromatography. 400 MHz Η NMR (CDC13) δ 8.04 (d, 2H), 7.70 (d, 2H), 7.08 (s, IH), 6.82 (s, IH), 5.23 (s, 2H), 3.88 (s, 3H), 3.70 (s, 3H), 3.52 (s, 2H), 2.50 (s, 3H), 2.39 (s, 3H). MS m/z 498 (M+1). Preparation of 2-[5-methoxy-2-methyl-4-({4-methyl-2-[4- (trifluoromethyl)phenyl](l,3-thiazol-5-yl)}methoxy)phenylthio]acetic acid (Compound 27)
The title compound was prepared in the manner analogous to Example 1 with the product from example 27C, and lithium hydroxide monohydrate in tetrahydrofuran/water mixture (10:1). MS m/z 483.87 (M+1).
Example 28
Synthesis of 2,2-difluoro-2-f5-methoxy-2-methyl-4-({4-methyl-2-r4- (trifluoromethyl)phenyl1(1.3-thiazol-5-yl))methoxy)phenylthiolacetic acid (Compound 28)
Figure imgf000097_0001
28
Preparation of 5-Methoxy-2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)- thiazol-5-ylmethoxy]-benzene disulfide (compound 28A)
Figure imgf000097_0002
28A The title compound was prepared from compound 27B and 0.2 M potassium dihydrogenphosphate in methanol in the manner analogous to Example 3C. 400 MHz Η NMR (DMSO-J6) δ 8.13 (d, 4H), 7.88 (d, 4H), 7.10 (s, 2H), 6.98 (s, 2H), 5.38 (s, 4H), 3.70 (s, 6H), 2.50 (s, 6H), 2.25 (s, 6H).
Preparation of ethyl 2,2-difluoro-2-[5-methoxy-2-methyl-4-({4-methyl-2-[4- (trifluoromethyl)phenyl](l,3-thiazol-5-yl)}methoxy)phenylthio]acetate (Compound 28B)
Figure imgf000098_0001
28B
The mixture of the product from example 28A, triphenylphospine, HCl in water and dioxane was heated at 60 °C for 12 h, then cooled to room temperature and concentrated in vacuo. The residue was dissolved in anhydrous acetonitrile, ethyl 2- bromo-2,2-difluoroacetate and cesium carbonate were added. The reaction mixture was stirred at room temperature for 2 h, then filtered through Celite . The filtrate was concentrated, and purified using normal phase chromatography to afford the title product. 400 MHz Η NMR (CDC13) δ 8.03 (d, 2H), 7.68 (d, 2H), 7.15 (s, IH), 6.90 (s, IH), 5.29 (s, 2H), 4.25 (q, 2H), 3.88 (s, 3H), 2.55 (s, 3H), 2.44 (s, 3H), 1.29 (t, 3H). Preparation of 2,2-difluoro-2-[5-methoxy-2-methyl-4-({4-methyl-2-[4- (trifluoromethyl)phenyl](l,3-thiazol-5-yl)}methoxy)phenyIthio]acetic acid (Compound 28)
The product from example 28B was dissolved in a mixture of methanol and water, then treated with sodium hydroxide. After stirring at 70 °C for 1 h, the reaction mixture was cooled to room temperature, and acidified to pH 3 with 1 N HCl. The white precipitate was collected by filtration, washed subsequently with water and hexanes, and dried in vacuo to afford the title product. MS m/z 520 (M+1).
Example 29
Synthesis of l-r{3-Methoxy-4-r4-methyl-2(4-trifluoromethylphenyl)thiazol-5- ylmethylsulfanyl1benzyl)pyrrolidine-2-carboxylic acid (Compound 29)
Figure imgf000099_0001
29
Preparation of Dimethylthiocarbamic acid O- (4-formyl-2methoxyphenyl) ester (compound 29A)
Figure imgf000099_0002
29A To a solution of vanillin in Dioxane, under nitrogen atmosphere, was added dimethylthiocarbonyl chloride, triethylamine, and DMAP. The resulting mixture was warmed to reflux and refluxed 16h, then diluted with water and extracted with EtOAc. The combined extracts were washed with water and brine, and the organic phase dried over sodium sulfate then concentrated. The residue was purified by recrystallization in MeOH and water to give 29A as a white solid, (mp 126-127°C) Analyzed for C13H,5NO2: Calc: C, 55.21 %; H, 5.48%; N, 5.85%; Found: C, 55.17%; H, 5.42%; N, 5.92%.
Preparation of 4-Mecapto-3-methoxybenzaldehyde (compound 29B)
Figure imgf000100_0001
29B
Compound 29A was heated to 230-240°C under nitrogen atmosphere for lh, then cooled to room temperature . The residue was dissolved in methano, placed under nitrogen atmosphere, and solution of 50% aqueous sodium hydroxide in water was added. The resulting mixture was refluxed for 16h, cooled to room temperature, acidified with 2N HCL and extracted with EtOAc. The combined extracts were washed with saturated aqueous sodium bicarbonate and brine. The organic phase was dried over sodium sulfate and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 10% EtOAc/Hexane) to give 29B as a yellow oil. NMR (400Mhz, CDC13) δ 3.96 (s, 3H), 4.16 (s, IH), 7.32-7.40 (m, 3H), 9.87 (s, IH). MS: (m+1) 169. Preparation of 3-Methoxy-4-[4-methyI-2-(4-trifluoromethylphenyl)thiazol-5- ylmethylsufanyl]benzaldehyde (compound 29C)
Figure imgf000101_0001
29C
To a solution of 29B in acetonitrile, under nitrogen atmosphere, was added 5- chloromethyl-4-methyl-2-(4-trifluoromethylphenyl)thiazole followed by cesium carbonate. The resulting mixture was stirred 16h, diluted with water. The precipitate was collected by filtration, dried, dissolved in ethyl ether, and filtered. The filtrate was concentrated under vacuum and the residue purified by flash chromatography (silica gel, 20% EtOAc/Hexane to give 29C as a yellow solid. NMR (400Mhz, CDC13) δ 2.55 (s, 3H), 3.92 (s, 3H), 4.74 (s, 2H), 7.46-7.50 (m, IH), 7.68-7.72 (m, 3H), 8.08-8.1 1 (m, 2H), 8.20-8.23 (m, IH), 9.89 (s, IH). MS: (m+1) 424.
Preparation of l-{3-Methoxy-4-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5- ylmethylsulfanyl]benzyl}pyrrolidine-2-carboxylic acid methyl ester (compound 29 D)
Figure imgf000101_0002
29D To a solution of 29C in THF and N,N'-dimethylethyleneurea under nitrogen atmosphere was added DL-methylproline hydrochloride. The resulting mixture was stirred until clear , then glacial acetic acid was added dropwise followed by sodium triacetoxyborohydride in small portions over 30 min. The reaction mixture was stirred 16h, quenched with water, and extracted with EtOAc. The combined extracts were washed with brine. The organic phase was dried over magnesium sulfate and concentrated under vacuum. The residue was purified by flash chromatography (silica gel, 20% EtOAc/Hexane) to give 29D as a yellow solid. NMR (400Mhz, CDC13) δ 2.03-2.20 (m, 2H), 2.22- 2.40 (m, 2H) 2.51 (s, 3H), 2.62-2.80 (m, IH) 3.38-3.45 (m, IH) 3.79 (s, 3H), 4.02-4.18 (m, 2H) 4.80 (s, 2H), 6.68-6.71 (m, 1/2H), 6.88-6.91 (m, 1/2H), 7.18 (d, J = 7Hz, 1/2H), 7.43 (d, J = 7Hz, 1/2H) 7.63-7.69 (m, 3H), 8.00 (d, J = 4,2H). MS: (m+1) 537.
Preparation of l-[{3-Methoxy-4-[4-methyl-2(4-trifluoromethylphenyl)thiazol-5- ylmethylsulfanyl]benzyl}pyrrolidine-2-carboxylic acid (Compound 29)
To a solution of 29D in methanol was added lithium hydroxide monohydrate. The resulting mixture was warmed to reflux and refluxed for 16h, then neutralized with IN aqueous HCl and diluted with water. The precipitate was collected, air dried, then triturated in EtOAc to give 29 as a white solid. MS: (m+1) 523.
Example 30
Synthesis of ({2-Methyl-4-r4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyll-phenoxyl-phenyl-acetic acid (Compound 30)
Figure imgf000102_0001
Preparation of 4-thiocyanato-2-methyl-phenol (compound 30A)
Figure imgf000103_0001
30A
The title compound was prepared in a manner analogous to compound 3A.
400 MHz Η NMR (DMSO- 6) δ 10.1 (s, IH), 7.36 (s, IH), 7.30 (d, IH, J =-8.1 Hz), 6.77 (d, IH, J = 8.1 Hz), 2.08 (s, 3H).
Preparation of (4-thiocyanato-2-methyl-phenoxy)-phenyl-acetic acid ethyl ester (Compound 30B)
Figure imgf000103_0002
30B
The title compound was prepared in a manner analogous to compound 3B by reacting copound 30A with bromo-phenyl-acetic acid ethyl ester. MS: (m+1 ) 328.
Preparation of (4-Mercapto-2-methyl-phenoxy)-phenyl-acetic acid ethyl ester (Compound 30C)
Figure imgf000103_0003
The title compound was prepared in a manner analogous to compound 3C. 400 MHz Η NMR (DMSO-dβ) δ 7.51 (d, 2H, J = 8.5 Hz), 7.35 (m, 3H), 7.07 (s, IH), 6.99 (d, IH, I = 10.5 Hz), 6.76 (d, IH, I = 10.5 Hz), 5.90 (s, IH), 5.03 (s, IH), 4.04 (m, 2H), 2.15 (s, 3H), 1.04 (t, 3H, 7 = 7.3 Hz). Prepa ration of {2-Methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy}-phenyl-acetic acid ethyl ester (Compound 30D)
Figure imgf000104_0001
The title compound was prepared in a manner analogous to compound IF, using compound 30C and IB. MS: (m+1 ) 558. Preparation of ({2-Methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy}-phenyl-acetic acid (Compound 30)
30D was saponified in the same manner as described for compound IF to give, after recrystalisation from CHCl3/hexanes, the title compound as a solid, m/z = 530 (M+1).
Example 31
Synthesis of {5-Chloro-2-methyl-4-r4-methyl-2-(4-trifluoromethyl-phenyl)- thiazol-5-ylmethylsulfanvn-phenoxyl-acetic acid (Compound 31)
Figure imgf000104_0002
31 Preparation of 5-Chloro-2-methyl-4-thiocyanato-phenol (compound 31A)
Figure imgf000105_0001
The title compound was prepared from 5-chloro-2-methyl-phenol in a manner analogous to compound 3A. MS m/z 199 (M+).
Preparation of (5-chloro-2-methyl-4-thiocyanato-phenoxy)-acetic acid methyl ester (Compound 31B)
Figure imgf000105_0002
31B
The title compound was prepared from compound 31A in a manner analogous to compound 3B. MS m/z 245 (M-CN).
Preparation of (5-chloro-4-mercapto-2-methyl-phenoxy)-acetic acid methyl ester (Compound 31 C)
Figure imgf000105_0003
31C
The title compound was prepared from compound 31B in a manner analogous to compound 3C. MS m/z 245 (M-l). Preparation of {5-Chloro-2-methyl-4-[4-methyl-2-(4-trifluoromethyl- phenyl)thiazol-5-ylmethylsulfanyl]-phenoxy}-acetic acid methyl ester (Compound 31 D)
Figure imgf000106_0001
31D
31C and 5-chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole (compound IB) were coupled in a similar manner as described for compound IF to provide, after purification by flash column chromatography (gradient elution: 5% EtOAc/hexanes to 35% EtOAc/hexanes), the title compound as a yellow solid. MS m/z 502 (M+1).
Preparation of {5-Chloro-2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)- thiaζol-5-ylmethylsulfanyl]-phenoxy}-acetic acid (Compound 31)
31D was saponified in the same manner as described for compound IF to give, after recrystalisation from CHCl3/hexanes, the title compound as a solid. MS m/z 488
(M+1).
Example 32 Synthesis of 2-r5-(methoxymethyl)-2-methyl-4-({4-methyl-2-r4- (trifluoromethyl)phenyll(l,3-thiazol-5-yl))methylthio)phenoxy1acetic acid
(Compound 32)
Figure imgf000107_0001
32
Preparation of 5-(hydroxymethyl)-2-methylphenol (Compound 32A)
Figure imgf000107_0002
32A
To 3-hydroxy-4-methylbenzoic acid in THF was added borane/THF complex (1.0 M solution) slowly at 0 °C under nitrogen. After completion of addition, the mixture was allowed to warm to room temperature, then heated at 70 °C for 2 h, cooled to room temperature again, 1 N HCl (150 ml) was added slowly and stirred at room temperature. The reaction mixture was concentrated in vacuo, then ethyl acetate was added, washed with brine, dried over sodium sulfate, and concentrated to give 32A in good purity. 400 MHz Η NMR (DMSO-d6) δ 9.19 (s, IH), 6.98 (d, IH), 6.77 (s, IH), 6.62 (d, IH), 5.03 (t, IH), 4.39 (d, 2H), 2.08 (s, 3H). Prepa ration of 5-(methoxymethyl)-2-methylphenol (Compound 32B)
Figure imgf000108_0001
32B
To a stirred solution of 32A in methanol was added concentrated sulfuric acid slowly at room temperature. The mixture was refluxed overnight. After cooling, pH was adjusted to 3 ~ 4 with 2 N sodium hydroxide and concentrated, then ethyl acetate was added, washed with brine, dried over sodium sulfate, and concentrated to give 32B in good purity. 400 MHz ]H NMR (DMSO-d6) δ 9.23 (brs, IH), 7.00 (d, IH), 6.76 (s, IH), 6.62 (d, IH), 4.29 (s, 2H), 3.23 (s, 3H), 2.10 (s, 3H).
Preparation of 5-Methoxymethyl-2-methyl-4-thiocyanato-phenoI (Compound
32C)
Figure imgf000108_0002
To a stirred solution of the product from example 32B, sodium thiocyanate, and sodium bromide in methanol at 0 °C was added a solution of bromine in methanol dropwise. After the completion of the bromine addition, the reaction mixture was stirred at room temperature for 1 h, then concentrated in vacuo. The resulting residue was taken up in ethyl acetate, washed with saturated sodium bicarbonate solution, brine, dried over sodium sulfate, concentrated, and purified using normal phase chromatography to afford the title product. 400 MHz Η NMR (DMSO- ) δ 10.18 (brs, IH), 7.46 (s, IH), 6.99 (s, IH), 4.48 (s, 2H), 3.32 (s, 3H), 2.17 (s, 3H).
Preparation of (5-Methoxymethyl-2-methyl-4-thiocyanato-phenoxy)-acetic acid methyl ester (Compound 32D)
Figure imgf000109_0001
The mixture of the product from example 32C, methyl bromoacetate, and cesium carbonate in anhydrous acetonitrile was heated at 60 °C for 2 h. After cooling, the reaction mixture was filtered through Celite®. The filtrate was diluted with diethyl ether, washed with brine, dried over sodium sulfate, and concentrated to give 32D. 440000 MMHHzz ΗΗ NNMMRR ((OOMMSSOO--dd66)) δδ 77..5588 (s, IH), 7.06 (s, IH), 4.96 (s, 2H), 4.50 (s, 2H), 3.74 (s, 3H), 3.32 (s, 3H), 2.22 (s, 3H).
Preparation of methyl 2-[5-(methoxymethyl)-2-methyl-4- sulfanylphenoxyjacetate (Compound 32E)
Figure imgf000109_0002
32E A solution of the product from example 32D, dithiothreitol, and 0.2 M potassium di hydro genphosphate in methanol was refluxed for 1 h under nitrogen, then cooled and concentrated in vacuo. The resulting residue was taken up in diethyl ether, and washed with brine, dried over sodium sulfate, concentrated, and purified using normal phase chromatography to afford the title product. 400 MHz Η NMR (CDC13) δ 7.17 (s, IH), 6.75 (s, IH), 4.63 (s, 2H), 4.44 (s, 2H), 3.80 (s, 3H), 3.45 (s, IH), 3.40 (s, 3H), 2.22 (s, 3H).
Preparation of methyl 2-[5-(methoxymethyl)-2-methyl-4-({4-methyl-2-[4- (trifluoromethyl)phenyl](l,3-thiazol-5-yl)}methylthio)phenoxy]acetate (Compound 32F)
Figure imgf000110_0001
32F
Compound 32E was dissolved in anhydrous acetonitrile, then 5-(chloromethyl)-4- methyl-2-[4-(trifluoromethyl)phenyl]-l ,3-thiazole was added followed by cesium carbonate. The mixture was stirred at room temperature for 2 h, then filtered through Celite®, concentrated, and purified using normal phase chromatography to afford the title product. 400 MHz Η NMR (CDC13) δ 7.98 (d, 2H), 7.65 (d, 2H), 7.21 (s, IH), 6.80 (s, IH), 4.69 (s, 2H), 4.48 (s, 2H), 4.1 1 (s, 2H), 3.80 (s, 3H), 3.37 (s, 3H), 2.22 (s, 3H), 2.19 (s, 3H). Preparation of 2-[5-(methoxymethyl)-2-methyl-4-({4-methyl-2-[4- (trifluoromethyl)phenyl](l,3-thiazol-5-yl)}methylthio)phenoxy]acetic acid (Compound 32)
The title compound was prepared in the manner analogous to Example 1 with the product from example 32F and lithium hydroxide monohydrate) in THF and water. MS m/z 498 (M+1 ).
Example 33 Synthesis of (4-(4-r4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyll-phenvU-cvclohexyP-acetic acid (Compound 33);
Figure imgf000111_0001
33
Preparation of [4-(4-ChlorosulfonyI-phenyl)-cyclohexyl]-acetic acid ethyl ester (compound 33A):
Figure imgf000111_0002
33A
Compound 33A was prepared as follows. Chlorosulfonic acid was cooled to 0 °C. Then (4-Phenyl-cyclohexyl)-acetic acid ethyl ester was added over 30 min. The - I l l-
mixture was stirred at RT for 3h and was poured into ice (lOOg). The cloudy solution was extracted with ether (2x50mL). The extracts were dried with magnesium sulfate and concentrated to give a brown oil which was passed through a short pad of silica gel to afford the desired product. MS 345 (M+1 )+
Preparation of [4-(4-Mercapto-phenyl)-cyclohexyl]-acetic acid methyl ester (Compound 33B):
Figure imgf000112_0001
33B
Compound 33A was refluxed with tin powder in MeOH and 4M HCl/dioxane. After 3h, the reaction mixture was poured into ice with CH2C12. The phases were separated and the aqueous layer was extracted with CH2C12. The combined organic layers were dried with magnesium sulfate, filtered and evaporated to give the crude thiol. The ethyl ester was completely transesterified to the methyl ester. MS 263 (M-l)+
Preparation of (4-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethy!sulfanyl]-phenyl}-cyclohexyI)-acetic acid methyl ester (Compound 33C):
Figure imgf000112_0002
33C
Compound 33B (crude mixture from above) was dissolved in acetonitrile with chloride 5-chloromethyl-4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole and Cs2CO3. The reaction mixture was stirred at RT overnight. Ether and water were added and stirring was continued for another 5 min. The layers were separated and the aqueous layer was extracted with ether. The combined organics were dried over MgSO and concentrated to an oil. The crude product was purified by column chromatography eluted with EtOAc and hexanes to give the desired product. MS 520 (M+1 )+
Preparation of (4-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenyl}-cyclohexyl)-acetic acid (Compound 33):
To a solution of 33C in MeOH and THF was added LiOH.H2O. After refluxing overnight, the solution was cooled to RT and solvents were removed. The residue was dissolved in water and neutralized with IN HCl. The cloudy solution was extracted with EtOAc and the extracts were dried with MgSO and concentrated. The crude product was purified by chromatography to afford the desired product. MS 506 (M+l)+
BIOLOGICAL ASSAYS
The compounds of the present invention have demonstrated PPAR modulating activity in the standard assays commonly employed by those skilled in the art. Accordingly, such compounds and formulations comprising such compounds are useful for treating, preventing or controlling hypercholesterolemia and hyperlipidemia.
A. Selectivity Measurements
1. Test A. Transient transfections assay using the HepG2 hepatoma cell line.
HepG2 cells were transiently transfected with an expression plasmids encoding hPPARα, hPPARβ or mPPARγ chimeric receptors and a reporter containing the yeast upstream activating sequence (UAS) upstream of the viral E1B promoter controlling a luciferase reporter gene. In addition, the plasmid pRSVβ-gal was used to control for transfection efficiency. HepG2 cells were grown in DMEM supplemented with 10%FBS and lμM non-essential amino acid. On the first day, cells were split into 100mm dishes at 2.5x 106 /dish and incubated overnight at
37C°/5% CO2. On the second day the cells were transiently transfected with plasmid DNA encoding a chimeric receptor, the luciferase reporter gene; and β-gal. For each 100 mm dish, 15μg of lucifease reporter (PG5Elb) DNA, 15μg of Gal4-PPAR chimeric receptor DNA, and 1.5μg of β-gal plasmid DNA were mixed with 1.4ml of opti-MEM in the tube. 28μl of LipoFectamine-2000 reagent was added to 1.4ml of opti-MEM in the tube, and incubate for 5 min at RT. The diluted Lipofectamine-2000 reagent was combined with the DNA mixture, and incubate for 20 min at RT. After fresh medium was added to each 100mm dish of cells, 2.8ml of Lipofectamine2000- DNA mixture was added dropwise to the 100mm dish containing 14ml of medium, and incubate 37°C overnight. On day three cells were trypsinized off thel 00 mm dishes and re-plated on 96 well plates. Cells were plated at 2.5x10 cells per well in 150μl of media and 50μl of compound diluted by media was added. The test compounds added were in the range from 50μM to 50pM. After addition of compounds, the plates were incubated at 37C° for 24 hours. Subsequently cells were washed with once with lOOμl of PBS, lysed, and processed for measuring luciferase and β-gal activity using Dual-Light luciferase kit from Tropix ®, according to the manufacturer's recommendations, on an EG&G Bethold MicroLumat LB96P luminometer. EC50 values were obtained using the GraphPad Prism™ program. Surprisingly, the compounds of the present invention exhibit activity for both PPARα and PPARβ. Accordingly, the compounds of the present invention should find considerable therapeutic applications for hypercholesterolemia and hyperlipidemia. The Hep G2-hBeta EC50 ("EC50-β") data as well as the Hep G2-hAlpha EC50 ("EC50. α") data of the compounds of the invention are presented in Table 2 below. Table 2
Figure imgf000115_0001
Table 2 Continued
Figure imgf000116_0001
B. Effect of PPAR-beta compounds on lipid and human apoprotein Al concentrations in the hApoAl transgenic mouse
Mice, transgenic for human apoAl, were purchased from Jackson laboratories. All animals were allowed normal chow (Ralston-Purina) and water ad libitum in temperature controlled rooms, under a 12-h light, 12-h dark cycle beginning with lights on at 6 AM. During the treatment phase of the study the mice were dosed daily between 6 and 9 AM by oral gavage using a suspension vehicle of 1.5% carboxymethylcellulose plus 0.2 percent Tween-20 (CMC/Tween) containing the specified compounds. Control animals received vehicle alone. Vehicle volume represented 0.25 percent of body weight. Under anesthesia, tail blood was obtained weekly in the morning at the indicated days of study. At termination, tissue samples (liver, intestine, fat, and muscle) were taken to study effects on genes effecting lipid metabolism. Each of the compounds of the present invention that were tested effected a significant increase in HDL over the values observe for the control animals. Furthermore, these compounds resulted in triglyceride levelswhich were lower than 16-
observed in controls. The compounds of the present invention exhibited a 61 to 123 mg/dL increase in HDL compared to a 44 mg/dL increase for the controls at the end of the study (day 16). Similarly, compounds of the present invention exhibited an increase on average for the HDL to (LDL + VLDL) ratio. This ratio was 14 to 18.3 at the beginning of the study. At the end of the study this ratio was found to be from 1 1.9 to 83.9. (Controls dropped from 15.5 to 1 1.9)
FORMULATIONS
The compounds of the present invention can be administered alone or in combination with one or more therapeutic agents. These include, for example, other agents for treating, preventing or controlling hypercholesteremia, hyperlipidemia, obesity, hyperglycemia, hypercholesteremia, hyperlipidemia, atherosclerosis, hypertriglyceridemia, and hyperinsulinemia.
The compounds are thus well suited to formulation for convenient administration to mammals for the prevention and treatment of such disorders.
The following examples further illustrate typical formulations provided by the invention.
Formulation 1
Figure imgf000117_0001
The above ingredients are mixed and dissolved in the saline for IV administration to a patient. Formulation 2
Figure imgf000118_0001
The ingredients are blended to uniformity and pressed into a tablet that is well suited for oral administration to a patient.
Formulation 3
Figure imgf000118_0002
The ingredients are combined and milled to afford material suitable for filling hard gelatin capsules administered to a patient.
Formulation 4
Figure imgf000118_0003
The ingredients are combined via melting and then poured into molds containing 2.5 g total weight. While embodiments of the invention have been illustrated and described, it is not intended that these embodiments illustrate and describe all possible forms of the invention. Rather, the words used in the specification are words of description rather than limitation, and it is understood that various changes may be made without departing from the spirit and scope of the invention.

Claims

What is claimed is:
1. A compound having Formula I:
Figure imgf000120_0001
or a pharmaceutically acceptable salt thereof, wherein:
W is O, S, CR5R6, -(CH2)p-cycloalkylene, or -(CH2)p-heterocycloalkylene;
X° and X1 are independently O or S;
Ar1 is a unsubstituted or substituted aryl or heteroaryl;
R1, R2, R3, and R4 are independently alkyl, lower alkoxy, haloalkyl,-O- (CH2)PCF3, halogen, nitro, cyano, -OH, -SH, -CF3, -S(O)palkyl, S(O)paryl, - (CH2)mOR7, -(CH2)mNR8R9, -COR7, -CO2H, -CO2R7, or -NR8R9;
R5 and R are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl, or joined together to form a 3 to 7 member cycloalkyl or cycloalkenyl;
R7 is independently hydrogen, alkyl, alkenyl, alkynyl, or aryl; R8 and R9 are each independently hydrogen, alkyl, alkenyl, alkynyl, -COalkyl, -COaryl, cycloalkyl, -CO alkyl, -CO ary1, -SO2alkyl, -SO aryl, or joined together to form a 4 to 7 member ring having 1 to 3 heteroatoms;
R10 and R11 are independently hydrogen, halo, aryl, or hereroaryl; m is 0 to 5; n is 0 to 5; and p is 0 to 2; with the following provisos: that when W is O, n = 1 , and R1 is hydrogen, R2 and R4 are not hydrogen or R2 and R3 are not hydrogen; that when W is O, n = 1, and R2 is hydrogen, R1 and R3 are not hydrogen or R1 and R4 are not hydrogen; that when W is O, n = 1 , and R3 is hydrogen, R1 and R4 are not hydrogen or R2 and R4 are not hydrogen; and that when W is O, n = 1 , and R4 is hydrogen, R1 and R3 are not hydrogen or
R2 and R are not hydrogen.
2. A compound of claim 1 , wherein W is O, Ar1 is 4-trifluoromethylphenyl, and n is
3. A compound of claim 1, wherein
W is O;
X° and X1 are S;
Ar1 is 4-trifluoromethylphenyl; R1 , R2, R3, and R4 are hydrogen, lower alkyl, lower alkoxy, -(CH2)mNR8R9, or
-(CH2)mOR7 ;
R7 is alkyl;
R8 and R9 are independently hydrogen, alkyl, or -COalkyl;
R10 and Rπ are hydrogen; m is 0 to 5; and n is 1.
4. A compound of claim 1 , wherein W is CR5R6, -(CH2)p-cycloalkylene, or -(CH2)p-heterocycloalkylene;
X° and X1 are independently O or S; Ar1 is unsubstituted or substituted aryl or heteroaryl; R1, R2, R3, and R4 are hydrogen, lower alkyl, lower alkoxy, haloalkyl,-O- (CH2)PCF3, halogen, nitro, cyano, -OH, -SH, -CF3, -S(O)palkyl, S(O)paryl, - (CH2)mOR7, -(CH2)mNR8R9, -COR7, -CO2H, -CO2R7, or -NR8R9;
R5 and R6 are joined together to form a 3 to 7 member cycloalkyl or cycloalkenyl;
R7 is independently hydrogen, alkyl, alkenyl, alkynyl, or aryl; R8and R9are independently hydrogen, alkyl, alkenyl, alkynyl, -COalkyl, - COaryl, cycloalkyl, -CO2alkyl, -CO2aryl, -SO2alkyl, -SO2aryl, or joined together to form a 4 to 7 member ring having 1 to 3 heteroatoms; m is 0 to 5; n is 0 to 5; and p is 0 to 2.
5. A compound of claim 4, wherein
W is CR5R6, cycloalkylene or -(CH2)-heterocycloalkylene; X° and X1 are S; Ar1 is 4-trifluoromethylphenyl; R1, R2, R3, and R4 are hydrogen, lower alkyl, lower alkoxy, halogen, -CF3, -
(CH2)mOR7, or -(CH2)mNR8R9;
R5 and R6 are joined together to form a 3 to 7 member cycloalkyl ring;
R7 is hydrogen, or alkyl;
R8 and R9 are independently hydrogen, alkyl, or -COalkyl; m is 0 to 5; and n is 0.
A compound of claim 4, wherein W is
Figure imgf000123_0001
X° and X1 are S; Ar1 is 4-trifluoromethylphenyl;
R1, R2, R3, and R4 are hydrogen, lower alkyl, lower alkoxy, halogen, -CF3, (CH2)mOR7, or -(CH2)mNR8R9;
R7 is independently hydrogen, or lower alkyl; o π
R and R are each independently hydrogen, or lower alkyl; m is 0 to 5; and n is 0.
7. A compound of claiml or4, wherein: R2 and R3 are hydrogen; and R1 and R4 are lower alkyl or lower alkoxy.
8. A compound of claiml or 4, wherein:
R2 and R3 are hydrogen; R1 is alkyl; and R4 is alkoxy.
9. A compound of claiml or 4, wherein: R2 and R3 are hydrogen; R1 is methyl, ethyl, isopropyl, n-propyl, t-butyl, n-butyl, or isobutyl; and R4 is methyoxy, ethoxy, isopropoxy, n-propoxy, t-butoxy, n-butoxy, or isobutoxy.
10. A compound selected from the group: {2,5-Dimethyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy}-acetic acid;
{5-Ethyl-2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy} -acetic acid;
{5-Isopropyl-2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanylj-phenoxy} -acetic acid;
{2,6-Dimethyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy}-acetic acid;
{5-Methoxy-2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy}-acetic acid; {2-Methoxy-5-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy}-acetic acid;
{3,5-Dimethyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy}-acetic acid;
{3-Methoxy-5-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanylj-phenoxy} -acetic acid;
{2-Isopropyl-5-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy}-acetic acid
{2,6-Diisopropyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy}-acetic acid; 2-Methyl-2-{4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanylj-phenyl }-propionic acid;
2-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]- phenyl }-cyclopropanecarboxylic acid; ]-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]- phenyl }-cyclopropanecarboxylic acid; l-{4-[4-Methyl-2-(4-trifluoromethyl -phenyl)-thiazol-5-ylmethylsulfanyl]- phenyl }-cyclopentanecarboxylic acid; 4-Methyl-4-{4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethy lsulfanyl]-phenyl}-pentanoic acid;
3-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]- phenoxyj-propionic acid;
2-{3-Methoxy-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenyl }-2-methyl-propionic acid;
3-Methyl-3-{4-[4-methyI-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanylj-phenyl }-butyric acid;
3-{2,4-Dimethoxy-5-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanylj-phenyl }-propionic acid; 3-{2,5-Dimethoxy-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenyl}-propionic acid;
{2,4-Dimethoxy-5-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl] }-acetic acid;
3-{4-[4-Methtyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-phenyl }- 2-pyrrol-l-yl-propionic acid;
3-{4-[4-Methtyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-phenyl }-
2-phenyl-propionic acid;
3-{4-[4-Methtyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]- phenyl}-2-pyrrol-l-yl-propionic acid; 2-[5-(acetylamino)-2-methyl-4-({4-methyl-2-[4-(trifluoromethyl)phenyl](l ,3- thiazol-5-yl) } methylthio)phenoxy]acetic acid;
2-[5-fluoro-2-methyl-4-({4-methyl-2-[4-(trifluoromethyl)phenyl](l ,3-thiazol-
5-yl) } methylthio)phenoxy]acetic acid; 2-[5-methoxy-2-methyl-4-({4-methyl-2-t4-(trifluoromethyl)phenyl](l ,3- thiazol-5-yl) } methoxy)phenylthio]acetic acid;
2,2-difluoro-2-[5-methoxy-2-methyl-4-({4-methyl-2-[4-
(trifluoromethyl)phenyl](l ,3-thiazol-5-yl)}methoxy)phenylthio]acetic acid; 1 -[{ 3-Methoxy-4-[4-methyl-2(4-trifluoromethylphenyl)thiazol-5- ylmethylsulfanyl]benzyl }pyrrolidine-2-carboxylic acid;
({2-Methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanyl]-phenoxy}-phenyl-acetic acid;
{5-Chloro-2-methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5- ylmethylsulfanylj-phenoxy} -acetic acid;
2-[5-(methoxymethyl)-2-methyl-4-({4-methyl-2-[4-
(trifluoromethyl)phenyl](l,3-thiazol-5-yl)}methylthio)phenoxy]acetic acid;
(4-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]- phenyl}cyclohexyl)-acetic acid; and pharmaceutically acceptable salts thereof.
1 1. A pharmaceutical composition comprising a compound of claim 1 , 4, or 10 and one or more pharmaceutically acceptable carriers, diluents, or excipients.
12. A method of treating, preventing or controlling hyperlipidemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of claim 1 , 4, or 10.
13. A method of treating, preventing or controlling hypercholesteremia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of claim 1 , 4, or 10.
14. A method of treating, preventing or controlling atherosclerosis in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of claim 1, 4, or 10.
15. A method of making a compound having Formula I:
Figure imgf000127_0001
the method comprising, reacting:
Figure imgf000127_0002
with:
Figure imgf000128_0001
wherein:
W is O, S, CR5R6, -(CH2)p-cycloalkylene, or -(CH2)p-heterocycloalkylene;
X° and X1 are independently O or S; Ar1 is a unsubstituted or substituted aryl or heteroaryl;
R1, R2, R3, and R4 are independently alkyl, lower alkoxy, haloalkyl,-O- (CH2)PCF3, halogen, nitro, cyano, -OH, -SH, -CF3, -S(O)palkyl, S(O)paryl, - (CH2)mOR7, -(CH2)mNR8R9, -COR7, -CO2H, -CO2R7, or -NR8R9;
R5 and R6 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl, or joined together to form a 3 to 7 member cycloalkyl or cycloalkenyl;
R7 is independently hydrogen, alkyl, alkenyl, alkynyl, or aryl;
R and R are each independently hydrogen, alkyl, alkenyl, alkynyl, -COalkyl, -COaryl, cycloalkyl, -CO2alkyl, -CO2aryl, -SO2alkyl, -SO2aryl, or joined together to form a 4 to 7 member ring having 1 to 3 heteroatoms; R12 is a lower alkyl;
X is a halogen; m is 0 to 5; n is 0 to 5; and p is 0 to 2; with the following provisos: that when W is O, n = 1 , Y is absent, and R1 is hydrogen, R2 and R4 are not hydrogen or R2 and R3 are not hydrogen; that when W is O, n = 1 , Y is absent, and R2 is hydrogen, R1 and R3 are not hydrogen or R1 and R4 are not hydrogen; that when W is O, n = 1 , Y is absent, and R3 is hydrogen, R1 and R4 are not hydrogen or R2 and R4 are not hydrogen; and that when W is O, n = 1 , Y is absent, and R4 is hydrogen, R1 and R3 are not hydrogen or R2 and R3 are not hydrogen.
PCT/IB2003/000708 2002-03-07 2003-02-24 Thiazole and oxazole derivatives which modulate ppar activity WO2003074050A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
MXPA04007564A MXPA04007564A (en) 2002-03-07 2003-02-24 Thiazole and oxazole derivatives which modulate ppar activity.
AU2003206059A AU2003206059A1 (en) 2002-03-07 2003-02-24 Thiazole and oxazole derivatives which modulate ppar activity
CN03805413.2A CN1750820A (en) 2003-02-24 2003-02-24 Thiazole and oxazole derivatives which modulate PPAR activity
KR10-2004-7013951A KR20040091693A (en) 2002-03-07 2003-02-24 Thiazole and oxazole derivatives which modulate ppar activity
APAP/P/2004/003124A AP2004003124A0 (en) 2002-03-07 2003-02-24 Thiazole and oxazole derivatives which modulate PPAR activity
EP03702943A EP1482935B1 (en) 2002-03-07 2003-02-24 Thiazole and oxazole derivatives which modulate ppar activity
BR0308277-6A BR0308277A (en) 2002-03-07 2003-02-24 Thiazole and oxazole derivatives that modulate ppar activity
JP2003572567A JP2005528348A (en) 2002-03-07 2003-02-24 Thiazole and oxazole derivatives that modulate PPAR activity
DE60323060T DE60323060D1 (en) 2002-03-07 2003-02-24 THIAZOL AND OXAZOLE DERIVATIVES AS PPAR MODULATORS
EA200400943A EA200400943A1 (en) 2002-03-07 2003-02-24 Thiazol and oxazole derivatives, which modulate ppar activity
CA002478520A CA2478520A1 (en) 2002-03-07 2003-02-24 Thiazole and oxazole derivatives which modulate ppar activity
IS7377A IS7377A (en) 2002-03-07 2004-07-29 Thiazole go oxazole derivatives that adjust PPAR activity
TNP2004000168A TNSN04168A1 (en) 2002-03-07 2004-09-03 THIAZOLE AND OXAZOLE DERIVATIVES THAT MODULATE PPAR ACTIVITY
NO20044242A NO20044242L (en) 2002-03-07 2004-10-06 Thiazole and oxazole derivatives that modulate PPAR activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36240202P 2002-03-07 2002-03-07
US60/362,402 2002-03-07

Publications (1)

Publication Number Publication Date
WO2003074050A1 true WO2003074050A1 (en) 2003-09-12

Family

ID=27789157

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/000708 WO2003074050A1 (en) 2002-03-07 2003-02-24 Thiazole and oxazole derivatives which modulate ppar activity

Country Status (29)

Country Link
US (1) US20030207924A1 (en)
EP (1) EP1482935B1 (en)
JP (1) JP2005528348A (en)
KR (1) KR20040091693A (en)
AP (1) AP2004003124A0 (en)
AR (1) AR038881A1 (en)
AT (1) ATE405260T1 (en)
AU (1) AU2003206059A1 (en)
BR (1) BR0308277A (en)
CA (1) CA2478520A1 (en)
CO (1) CO5601012A2 (en)
DE (1) DE60323060D1 (en)
EA (1) EA200400943A1 (en)
EC (1) ECSP045285A (en)
ES (1) ES2310650T3 (en)
HN (1) HN2003000090A (en)
IS (1) IS7377A (en)
MA (1) MA27181A1 (en)
MX (1) MXPA04007564A (en)
NO (1) NO20044242L (en)
OA (1) OA12780A (en)
PA (1) PA8567801A1 (en)
PE (1) PE20030989A1 (en)
PL (1) PL372969A1 (en)
TN (1) TNSN04168A1 (en)
TW (1) TW200305403A (en)
UY (1) UY27695A1 (en)
WO (1) WO2003074050A1 (en)
ZA (1) ZA200406068B (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1737809A2 (en) * 2004-02-27 2007-01-03 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2007003581A1 (en) 2005-06-30 2007-01-11 Novo Nordisk A/S Phenoxy acetic acids as ppar delta activators
WO2006127503A3 (en) * 2005-05-20 2007-08-30 Amgen Inc Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
US7572934B2 (en) 2007-04-16 2009-08-11 Amgen Inc. Substituted biphenyl GPR40 modulators
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
US7687526B2 (en) 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
US7714008B2 (en) 2006-09-07 2010-05-11 Amgen Inc. Heterocyclic GPR40 modulators
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
US7968723B2 (en) 2004-05-05 2011-06-28 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US8153694B2 (en) 2005-07-29 2012-04-10 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US8217064B2 (en) 2007-12-20 2012-07-10 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
EP2540711A1 (en) * 2010-02-25 2013-01-02 SNU R & DB Foundation Selenalzole derivative having ligand which activates peroxisome proliferator activated receptor (ppar), preparing method thereof and usage of the chemical compounds
US8450522B2 (en) 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US8748462B2 (en) 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
US10456406B2 (en) 2013-09-09 2019-10-29 Vtv Therapeutics Llc Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb
US11931365B2 (en) 2023-01-25 2024-03-19 Reneo Pharmaceuticals, Inc. Use of PPAR-delta agonists in the treatment of disease

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
MXPA05012459A (en) * 2003-05-19 2006-02-22 Irm Llc Immunosuppressant compounds and compositions.
WO2005115384A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
RU2006145872A (en) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) SUBSTITUTED TRIAZOLES AS PPAR MODULATORS AND METHODS FOR PRODUCING THEM
WO2006121223A1 (en) * 2005-05-07 2006-11-16 Heon Joong Kang Process for preparing ligands of ppardelta and the intermediate compounds for preparing the same
JP2009132620A (en) * 2006-03-07 2009-06-18 Astellas Pharma Inc Phenylthiazole derivative
AU2008338963A1 (en) * 2007-12-13 2009-06-25 Sri International PPAR-delta ligands and methods of their use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0930299A1 (en) * 1996-08-19 1999-07-21 Japan Tobacco Inc. Propionic acid derivatives and applications thereof
WO2001000603A1 (en) * 1999-06-25 2001-01-04 Glaxo Group Limited Thiazole and oxazole derivatives and their pharmaceutical use
WO2002050047A1 (en) * 2000-12-20 2002-06-27 Glaxo Group Limited Substitued oxazoles and thiazoles as hppar alpha agonists
WO2002062774A1 (en) * 2000-12-20 2002-08-15 Glaxo Group Limited Thiazole derivatives for treating ppar related disorders
WO2002092590A1 (en) * 2001-05-11 2002-11-21 Glaxo Group Limited Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors
WO2002100403A1 (en) * 2001-06-07 2002-12-19 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (ppar)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0930299A1 (en) * 1996-08-19 1999-07-21 Japan Tobacco Inc. Propionic acid derivatives and applications thereof
WO2001000603A1 (en) * 1999-06-25 2001-01-04 Glaxo Group Limited Thiazole and oxazole derivatives and their pharmaceutical use
WO2002050047A1 (en) * 2000-12-20 2002-06-27 Glaxo Group Limited Substitued oxazoles and thiazoles as hppar alpha agonists
WO2002062774A1 (en) * 2000-12-20 2002-08-15 Glaxo Group Limited Thiazole derivatives for treating ppar related disorders
WO2002092590A1 (en) * 2001-05-11 2002-11-21 Glaxo Group Limited Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors
WO2002100403A1 (en) * 2001-06-07 2002-12-19 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (ppar)

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649110B2 (en) 2004-02-27 2010-01-19 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US7816367B2 (en) 2004-02-27 2010-10-19 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
EP1737809A4 (en) * 2004-02-27 2007-10-17 Amgen Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
EP1737809A2 (en) * 2004-02-27 2007-01-03 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US7968723B2 (en) 2004-05-05 2011-06-28 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
WO2006127503A3 (en) * 2005-05-20 2007-08-30 Amgen Inc Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
US8426473B2 (en) 2005-06-30 2013-04-23 High Point Pharnaceuticals, LLC Phenoxy acetic acids as PPAR delta activators
EP2298742A1 (en) 2005-06-30 2011-03-23 High Point Pharmaceuticals, LLC Phenoxy acetic acids as PPAR delta activators
US7943669B2 (en) 2005-06-30 2011-05-17 High Point Pharmaceuticals, Llc Phenoxy acetic acids as PPAR delta activators
US8217086B2 (en) 2005-06-30 2012-07-10 High Point Pharmaceuticals, Llc Phenoxy acetic acids as PPAR delta activators
WO2007003581A1 (en) 2005-06-30 2007-01-11 Novo Nordisk A/S Phenoxy acetic acids as ppar delta activators
US8153694B2 (en) 2005-07-29 2012-04-10 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
US11420929B2 (en) 2005-12-22 2022-08-23 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US9855274B2 (en) 2005-12-22 2018-01-02 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US10471066B2 (en) 2005-12-22 2019-11-12 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
EP2386540A1 (en) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
US9663481B2 (en) 2005-12-22 2017-05-30 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPARδ agonists
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US10947180B2 (en) 2005-12-22 2021-03-16 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US8362016B2 (en) 2005-12-22 2013-01-29 High Point Pharmaceuticals, Llc Phenyl propionic acids as PPAR delta activators
US8551993B2 (en) 2005-12-22 2013-10-08 High Point Pharmaceuticals, Llc Phenoxy acetic acids as PPAR delta activators
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
US7714008B2 (en) 2006-09-07 2010-05-11 Amgen Inc. Heterocyclic GPR40 modulators
US8003648B2 (en) 2006-09-07 2011-08-23 Amgen Inc. Heterocyclic GPR40 modulators
US7687526B2 (en) 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
US7572934B2 (en) 2007-04-16 2009-08-11 Amgen Inc. Substituted biphenyl GPR40 modulators
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
US8217064B2 (en) 2007-12-20 2012-07-10 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
US8450522B2 (en) 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
US8748462B2 (en) 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
EP2540711A4 (en) * 2010-02-25 2014-01-22 Snu R&Db Foundation Selenalzole derivative having ligand which activates peroxisome proliferator activated receptor (ppar), preparing method thereof and usage of the chemical compounds
EP2540711A1 (en) * 2010-02-25 2013-01-02 SNU R & DB Foundation Selenalzole derivative having ligand which activates peroxisome proliferator activated receptor (ppar), preparing method thereof and usage of the chemical compounds
US10456406B2 (en) 2013-09-09 2019-10-29 Vtv Therapeutics Llc Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
US11096946B2 (en) 2013-09-09 2021-08-24 Vtv Therapeutics Llc Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb
US11931365B2 (en) 2023-01-25 2024-03-19 Reneo Pharmaceuticals, Inc. Use of PPAR-delta agonists in the treatment of disease

Also Published As

Publication number Publication date
TNSN04168A1 (en) 2007-03-12
PE20030989A1 (en) 2003-11-29
EP1482935A1 (en) 2004-12-08
NO20044242L (en) 2004-10-06
HN2003000090A (en) 2004-05-05
US20030207924A1 (en) 2003-11-06
PA8567801A1 (en) 2003-11-12
IS7377A (en) 2004-07-29
JP2005528348A (en) 2005-09-22
ES2310650T3 (en) 2009-01-16
ZA200406068B (en) 2005-09-06
KR20040091693A (en) 2004-10-28
PL372969A1 (en) 2005-08-08
TW200305403A (en) 2003-11-01
EA200400943A1 (en) 2005-02-24
DE60323060D1 (en) 2008-10-02
MXPA04007564A (en) 2004-11-10
EP1482935B1 (en) 2008-08-20
UY27695A1 (en) 2003-10-31
AR038881A1 (en) 2005-02-02
AP2004003124A0 (en) 2004-09-30
AU2003206059A1 (en) 2003-09-16
BR0308277A (en) 2004-12-28
ECSP045285A (en) 2004-10-26
MA27181A1 (en) 2005-01-03
CA2478520A1 (en) 2003-09-12
CO5601012A2 (en) 2006-01-31
OA12780A (en) 2006-07-07
ATE405260T1 (en) 2008-09-15

Similar Documents

Publication Publication Date Title
EP1482935B1 (en) Thiazole and oxazole derivatives which modulate ppar activity
US6833380B2 (en) Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) Compounds that modulate PPAR activity and methods of preparation
JP3490704B2 (en) Thiazole and oxazole derivatives and their pharmaceutical use
CZ20031737A3 (en) Thiazole derivatives
AU2003212578A1 (en) Compounds that modulate ppar activity and methods for their preparation
EP2061760A1 (en) Benzo-fused compounds for use in treating metabolic disorders
KR20020058073A (en) Substituted Oxazoles and Thiazoles Derivatives as hPPAR Alpha Activators
JP2004532266A (en) Thiazole or oxazole derivatives useful for treating cardiovascular diseases
CA2626483A1 (en) Compounds and compositions as ppar modulators
MXPA04007177A (en) Low phosphorus animal feed and method for making same.
JP2007508270A (en) I. A. Thiazole-2-carboxamide derivatives for use as HPPAR agonists in the treatment of dyslipidemia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1-2004-501342

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2004/06068

Country of ref document: ZA

Ref document number: 200406068

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2213/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 163319

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/007564

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 534561

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 20040310

Country of ref document: UZ

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2003206059

Country of ref document: AU

Ref document number: 200400943

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: P-734/04

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: AP/P/2004/003124

Country of ref document: AP

Ref document number: 2478520

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003572567

Country of ref document: JP

Ref document number: 1020047013951

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 8397

Country of ref document: GE

Ref document number: 20038054132

Country of ref document: CN

Ref document number: 372969

Country of ref document: PL

Ref document number: P20040811A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 2003702943

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1200401019

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020047013951

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003702943

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020047013951

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2003702943

Country of ref document: EP